



Vaccines and Global Health: The Week in Review
17 July 2021 :: Issue 616
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 23,000 entries.

Comments and suggestions should be directed to

*David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org*

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.

Contents [click on link below to move to associated content]

- A. Milestones :: Perspectives :: Featured Journal Content
- B. Emergencies
- C. [WHO; CDC \[U.S., Africa, China\]](#)
- D. [Announcements](#)
- E. [Journal Watch](#)
- F. [Media Watch](#)

:::::
:::::

COVID-19 pandemic leads to major backsliding on childhood vaccinations, new WHO, UNICEF data shows

23 million children missed out on basic childhood vaccines through routine health services in 2020, the highest number since 2009 and 3.7 million more than in 2019

GENEVA/NEW YORK, 15 July 2021 --- 23 million children missed out on basic vaccines through routine immunization services in 2020 – 3.7 million more than in 2019 - according to official data published today by WHO and UNICEF. This latest set of comprehensive worldwide childhood immunization figures, **the first official figures to reflect global service disruptions due to COVID-19, show a majority of countries last year experienced drops in childhood vaccination rates.**

Concerningly, most of these – up to 17 million children – likely did not receive a single vaccine during the year, widening already immense inequities in vaccine access. Most of these children live in communities affected by conflict, in under-served remote places, or in informal or slum settings where they face multiple deprivations including limited access to basic health and key social services.

“Even as countries clamour to get their hands on COVID-19 vaccines, we have gone backwards on other vaccinations, leaving children at risk from devastating but preventable diseases like measles, polio or meningitis,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Multiple disease outbreaks would be catastrophic for communities and health systems already battling COVID-19, making it more urgent than ever to invest in childhood vaccination and ensure every child is reached.”

In all regions, rising numbers of children miss vital first vaccine doses in 2020; millions more miss later vaccines

Disruptions in immunization services were widespread in 2020, with **the WHO Southeast Asian and Eastern Mediterranean Regions most affected.** As access to health services and immunization outreach were curtailed, the number of children not receiving even their very first vaccinations increased in all regions. As compared with 2019, 3.5 million more children missed their first dose of diphtheria, tetanus and pertussis vaccine (DTP-1) while 3 million more children missed their first measles dose.

“This evidence should be a clear warning – the COVID-19 pandemic and related disruptions cost us valuable ground we cannot afford to lose – and the consequences will be paid in the lives and wellbeing of the most vulnerable,” said Henrietta Fore, UNICEF Executive Director. “Even before the pandemic, there were worrying signs that we were beginning to lose ground in the fight to immunize children against preventable child illness, including with the widespread measles outbreaks two years ago. The pandemic has made a bad situation worse. With the equitable distribution of COVID-19 vaccines at the forefront of everyone’s minds, we must remember that vaccine distribution has always been inequitable, but it does not have to be.”...

Table 1: Countries with the greatest increase in children not receiving a first dose of diphtheria-tetanus-pertussis combined vaccine (DTP-1)

	2019	2020
India	1'403'000	3'038'000
Pakistan	567'000	968'000
Indonesia	472'000	797'000
Philippines	450'000	557'000
Mexico	348'000	454'000
Mozambique	97'000	186'000
Angola	399'000	482'000
United Republic of Tanzania	183'000	249'000
Argentina	97'000	156'000
Venezuela (Bolivarian Republic of)	75'000	134'000
Mali	136'000	193'000

...“These are alarming numbers, suggesting the pandemic is unravelling years of progress in routine immunization and exposing millions of children to deadly, preventable diseases”, said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “This is a wake-up call – we cannot allow a legacy of COVID-19 to be the resurgence of measles, polio and other killers. We all need to work together to help countries both defeat COVID-19, by ensuring global, equitable access to vaccines, and get routine immunization programmes back on track. The future health and wellbeing of millions of children and their communities across the globe depends on it.”

Concerns are not just for outbreak-prone diseases. Already at low rates, vaccinations against human papillomavirus (HPV) - which protect girls against cervical cancer later in life - have been highly affected by school closures. As a result, across countries that have introduced HPV vaccine to date,

approximately 1.6 million more girls missed out in 2020. **Globally only 13 per cent of girls were vaccinated against HPV, falling from 15 per cent in 2019.**

Agencies call for urgent recovery and investment in routine immunization

As countries work to recover lost ground due to COVID-19 related disruptions, UNICEF, WHO and partners like Gavi, the Vaccine Alliance are supporting efforts to strengthen immunization systems by:

- Restoring services and vaccination campaigns so countries can safely deliver routine immunization programmes during the COVID-19 pandemic;
- Helping health workers and community leaders communicate actively with caregivers to explain the importance of vaccinations;
- Rectifying gaps in immunization coverage, including identifying communities and people who have been missed during the pandemic.
- Ensuring that COVID-19 vaccine delivery is independently planned for and financed and that it occurs alongside, and not at the cost of childhood vaccination services.
- Implementing country plans to prevent and respond to outbreaks of vaccine-preventable diseases, and strengthen immunization systems as part of COVID-19 recovery efforts
-

The agencies are working with countries and partners to deliver the ambitious targets of the global Immunization Agenda 2030, which aims to achieve 90% coverage for essential childhood vaccines; halve the number of entirely unvaccinated, or 'zero dose' children, and increase the uptake of newer lifesaving vaccines such as rotavirus or pneumococcus in low and middle-income countries.

:::::

:::::

COVAX

CEPI launches COVAX Marketplace to match buyers and sellers of critical manufacturing supplies and speed up global access to COVID-19 vaccines through COVAX

15 July 2021, Oslo, Norway – The Coalition for Epidemic Preparedness Innovations (CEPI) and COVAX partners are launching an innovative 'marketplace' to accelerate the global production of COVID-19 vaccine doses for COVAX by matching suppliers of critical inputs with vaccine manufacturers who urgently need them to produce vaccines for fair and equitable distribution through COVAX. This initiative is a key deliverable of the [COVAX Manufacturing Task Force](#), which is co-led by COVAX and industry partners [1].

In the past year unprecedented efforts by vaccine manufacturers and suppliers of vaccine components have aimed to triple previous annual vaccine output, scaling up to produce an estimated 11 billion doses of COVID-19 vaccine by the end of 2021 [2,3]. As a result of this historic scaling up, bottlenecks are affecting the global supply chain leading to acute shortages of vital supplies which are preventing COVID-19 vaccine manufacturers from operating at full capacity. This is delaying vaccine production and contributing to inequity.

The new COVAX Marketplace announced today is designed to address short-term bottlenecks by facilitating access to supplies needed to produce COVID-19 vaccines intended for distribution through COVAX. It will provide a secure platform for vaccine manufacturers and suppliers of critical inputs to confidentially indicate their needs or available supplies to CEPI, in its role as facilitator. CEPI will identify matching offers and requests and connect potential

matches, prioritising based on objective criteria including whether the manufacturer has a COVAX advance purchase agreement and WHO EUL in place, as well as dose volumes and delivery timings. Future versions of the Marketplace may include supplies required to manufacture other lifesaving therapies and vaccines which are also being affected by current global supply shortages.

The Marketplace is expected to improve the free flow of critical COVID-19 vaccine supplies by:

- Providing suppliers with a platform to allocate and reallocate unused materials.
- Mobilizing idle stock from vaccines and candidates that fail prior to gaining regulatory approval – as well as from those that might scale down their production in the future.
- Mobilizing potential surplus stock from manufacturers with non-vaccine activities.

Vaccine manufacturing processes are highly complex and expanding manufacturing capacity requires managing intricate cross-border supply chains frequently involving more than 100 components. Participants will be able to offer and request any materials required for vaccine production through the COVAX Marketplace, but it will initially focus on six categories of supplies which have been identified as critical: bioreactor bags, single use assemblies, cell culture media, filters, lipids, vials and stoppers.

Towards a scalable Marketplace platform

The COVAX Marketplace launching today is an initial version which aims to respond quickly to immediate market needs and bottlenecks. It will launch with approximately 10 – 15 participants, comprising COVAX vaccine manufacturers and suppliers of the key materials which have been identified as being most urgently needed. In parallel, in consultation with stakeholders CEPI is urgently exploring extending the Marketplace to include additional participants such as vaccine manufacturers with unused inputs – including those with failed products – Contract Development and Manufacturing Organizations (CDMOs), and pharmaceutical companies not currently involved in COVID-19 vaccine production. This would provide a platform to resolve supply bottlenecks which could extend beyond COVID-19 vaccines to other lifesaving therapies and vaccines which are being impacted by the current supply situation.

Prospective participants in the Marketplace are encouraged to visit the [COVAX Marketplace webpage](#) and submit an expression of interest at marketplace@cepi.net.

Dr Richard Hatchett, CEPI CEO, said: "Vaccine manufacturers have described the ways in which shortages of critical supplies have limited the speed and scale at which vaccines can be produced, which means many vaccine production lines haven't been operating at full capacity. **Optimizing the use of scarce resources that may otherwise be sitting idle – by matching buyers and sellers around the globe – could contribute to improving the global supply of vaccines through COVAX.** The pandemic has led to extraordinary innovation in vaccine development and production, and the COVAX Marketplace is an example of how we must continue to look beyond business as usual to find pragmatic solutions to fixable problems – such as supply chain bottlenecks – so that we can urgently unlock more COVID-19 vaccine doses for COVAX."...

::::::

US-donated vaccine deliveries to Africa set to begin, with first deliveries planned to Burkina Faso, Djibouti, and Ethiopia

16 July 2021 – Following close collaboration between the African Union (AU)/ African Vaccine Acquisition Trust (AVAT), COVAX and the United States Government, AU Member States are set to receive approximately 25 million COVID-19 vaccines to enhance coverage across the continent – contributing to the AU target of vaccinating at least 60% of the African population. The shipments of these donated doses follow from the pledge made by President Biden, President of the United States of America in May to share 80 million doses globally.

The first shipments, planned for the coming days, will see nearly a million doses of the Johnson & Johnson COVID-19 vaccine delivered to Burkina Faso, Djibouti, and Ethiopia.

In total, approximately 25 million doses of COVID-19 vaccines will be made available to 49 African countries in the coming weeks. The African Union/Africa CDC, AVAT, AFreximbank, COVAX and the US Government have collaborated fully in this process and will continue to support countries' access to COVID-19 vaccines and readiness for delivery...

Gavi signs agreements with Sinopharm and Sinovac for immediate supply to COVAX

- The signed advance purchase agreements will make doses available to COVAX starting from July to help address immediate and critical gaps in supply
- Addition of the Sinopharm and Sinovac vaccines, which have already been granted WHO Emergency Use Listing (EUL), further diversifies the Gavi-managed COVAX Facility portfolio, which now includes 11 vaccines and vaccine candidates
- Gavi CEO Seth Berkley: "I welcome today's agreements, which will make doses immediately available to COVAX participants."

Geneva, 12 July 2021 – Gavi, the Vaccine Alliance announced today that it had signed advance purchase agreements (APAs) with Sinopharm for its "BBIBP-CorV" inactivated virus vaccine against COVID-19 as well as with Sinovac for its inactivated virus vaccine against COVID-19, "CoronaVac". The agreements, which come at a time when the Delta variant is posing a rising risk to health systems, will begin to make 110 million doses immediately available to participants of the COVAX Facility, with options for additional doses.

The Sinopharm APA enables Q3 supply, with Gavi committing to purchase, on behalf of the COVAX Facility, 60 million doses that will be made available from July through October 2021. In addition, Gavi has the option to purchase a further 60 million doses in Q4 2021 and 50 million more doses in the first half of 2022, if necessary. This equates to a potential total of 170 million doses of the Sinopharm vaccine that could be made available to self-financing participants of the Facility as well as participants supported by the Gavi COVAX Advance Market Commitment (AMC).

The Sinovac APA also enables Q3 supply, with Gavi committing to purchase, on behalf of the COVAX Facility, 50 million doses to be made available from July through September 2021. In addition, Gavi has the option to purchase a further 150 million doses in Q4 2021 and 180 million more doses in the first half of 2022. In total, up to 380 million potential doses of the Sinovac vaccine could be available to both self-financing participants of the Facility as well as those supported by the Gavi COVAX AMC.

"I welcome today's agreements with Sinopharm and Sinovac, which will make doses immediately available to COVAX participants," said Dr Seth Berkley, CEO of Gavi. "This is yet another example of Gavi's active portfolio management strategy, ensuring the Facility has options in the face of constraints such as supply delays. Thanks to this deal, and because these vaccines have already received WHO Emergency Use Listing, we can move to start supplying doses to countries immediately."

Gavi and COVAX partners will now move quickly to ensure all the critical elements required before doses can be shipped – including official allocation by the Facility, UNICEF and PAHO procurement agreements, among others – are in place...

:::::

:::::

WHO SAGE Roadmap For Prioritizing Uses Of COVID-19 Vaccines In The Context Of Limited Supply

An approach to inform planning and subsequent recommendations based upon epidemiologic setting and vaccine supply scenarios

16 July 2021

Overview

Given the urgency and wide-ranging effects of the COVID-19 pandemic, SAGE has developed an approach to help inform deliberation around the range of recommendations that may be appropriate under different epidemiologic and vaccine supply conditions. To assist in developing recommendations for use of vaccines against COVID-19, SAGE proposes a Roadmap for Prioritizing Uses of COVID-19 Vaccines that considers priority populations for vaccination based on epidemiologic setting and vaccine supply scenarios. This Roadmap builds on the WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination.

(New version from 16 July 2021). <https://apps.who.int/iris/bitstreams/1357250/retrieve>

:::::

:::::

Carrying Equity in COVID-19 Vaccination Forward: Guidance Informed by Communities of Color

Publisher: The Johns Hopkins Center for Health Security

Authors: Brunson EK, Schoch-Spana M, Carnes M, Hosangadi D, Long R, Ravi S, Taylor M, Trotocaud M, Veenema TG, on behalf of the CommuniVax Coalition

Date posted: July 14, 2021 :: 71 pages

[View full report \(PDF\)](#)

Introduction:

Seven months into the COVID-19 vaccination campaign in the United States, nearly 50% of the American population has been vaccinated. While this is a monumental accomplishment, there is still much work to do.

In the coming months, the country will face a series of vaccination challenges including serving groups with persistently low vaccine uptake (due to, for example, low/no access, vaccine hesitancy, or a combination of factors), expanding COVID-19 vaccination to children (particularly those whose parents may be less willing to vaccinate their children than to get vaccinated themselves), and orchestrating a potential booster dose campaign (with its own hesitancy issues). As the COVID-19 vaccination campaign continues, lessons from the vaccine rollout to date can help provide direction moving forward.

One challenge that deserves closer attention and more refined solutions is the campaign's limited success at delivering vaccines to low-income persons and communities of color. During the pandemic, these populations have experienced significant physical, financial, and psychological harms at a disproportionate rate. The continued emergence and spread of new SARS-CoV-2 virus variants and the

resumption of routine social, commercial, and educational activities across the country amplify the risks that COVID-19 poses to these groups.

This report provides specific guidance on adapting COVID-19 vaccination efforts to achieve greater vaccine coverage in underserved populations and, through this, to develop sustainable, locally appropriate mechanisms to advance equity in health.

In the first half of the report, we outline findings from local, ethnographic research conducted within Black and Hispanic/Latino communities in Alabama, California, Idaho, Maryland, and Virginia. Since January, local research teams have been assessing community infrastructure; listening to community members, public health officials, and government leaders; and coordinating engagement activities to understand how best to promote awareness of, access to, and acceptability of COVID-19 vaccines. In the second half of this report, we present the policy and practice implications of the local research. The Working Group on Equity in COVID-19 Vaccination—an advisory body of community advocates, public health experts, and social scientists—developed the recommendations, eliciting local team feedback.

:::::
:::::

COVID

Editor's Note:

As is obvious to all, the sheer volume of strategic announcements, regulatory actions, country program decisions, commentary, and, indeed, misinformation around COVID response continues at extraordinary levels. Our weekly digest strives to present a coherent and comprehensive snapshot, but cannot be exhaustive. If you recognize a missed strategic development, a new source of rigorous analysis, or an insight/commentary that would benefit our common understanding, please advise me...we will review all suggestions and consider for inclusion in a subsequent edition:

david.r.curry@ge2p2global.org

We are seeking access to modelling which engages scenarios and articulates imperatives around a pandemic end-game through at least a 2025 horizon. We assess that WHO must be conducting or contracting for such modeling – or should recognize an imperative to be doing so in its global health governance role. If we have missed such modeling in progress, we would be delighted to be advised of it and will include it in our coverage.

:::::
:::::

COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out

Jul 17, 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

Global COVID-19 Figures: 189M total confirmed cases; 4.1M total confirmed deaths

Global vaccines administered: 3.58B

Number of Countries: 26 [26]

COVAX First Allocations (Number of Doses): 73M [73M]

COVAX Delivered (Number of Doses): 22M [22M]

Other Delivered (Number of Doses): 52M [51M]
Total Delivered (Number of Doses): 75M [73M]
Total Administered (Number of Doses): 70M [61M]

:::::::
:::::::

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 2 Jul 2021

Confirmed cases ::	188 655 968	[week ago: 185 291 530]
Confirmed deaths ::	4 067 517	[week ago 4 010 834]
Vaccine doses administered:	3 402 275 866	[week ago: 3 078 787 056]

:::::::

16 July 2021 *Speech*

[**WHO Director-General's opening remarks at the first meeting of the working group on strengthening WHO preparedness and response to health emergencies**](#)

[**WHO Director-General's opening remarks at the media briefing on COVID-19 – 15 July 2021**](#)

15 July 2021

- I would especially like to express my concern and condolences over the floods that are currently affecting Germany. I offer my deep condolences to those who have lost someone they love, and my sincere hopes that those who are missing will be found soon.
- Since 2020, Germany contributed close to 750 million US dollars to WHO, including more than 500 million dollars to support the COVID-19 response. Germany was also one of the main drivers behind the formation of the Access to COVID-19 Tools Accelerator last year, and we are very grateful for the further contribution of 260 million euros and 30 million vaccine doses that Minister Spahn has just announced. We will be signing the agreement under the WHO Strategic Preparedness and Response plan after today's press conference.
- As you know, the **WHO Emergency Committee met yesterday and will publish its statement shortly. The Committee has expressed concern that the pandemic is being mischaracterized as coming to an end when it is nowhere near finished. It has also warned about the strong likelihood for the emergence and global spread of new and possibly more dangerous variants of concern that may be even more challenging to control.**
- **The Committee also expressed deep concern about the level of funding for WHO's Strategic Preparedness and Response Plan for COVID-19**, which constrains WHO's ability to coordinate the global response to the pandemic, particularly in terms of having the flexibility we need to move at the speed this virus moves. And the committee has called on all countries to support WHO's call to vaccinate at least 10% of the population of every country by the end of September.

:::::::

Statement on the eighth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic

15 July 2021

...The Committee discussed key themes including:

- global inequitable access to COVID-19 vaccines which is compounded by use of the available vaccines beyond SAGE recommended priority populations and the administration of booster doses while many countries do not have sufficient access to initial doses;
- the need for technology transfer to enhance global vaccination production capacity,
- the importance of adapting PHSM to epidemiological and socio-economic contexts and to diverse types of gatherings,
- challenges posed by the lack of harmonization in documentation requirements for vaccination and recovery status for international travel,
- threats posed by current and future SARS CoV-2 variants of concern, and
- efforts made by some States Parties to apply a risk-management approach to religious or sports-based mass gathering events.

...The Committee unanimously agreed that the COVID-19 pandemic still constitutes an extraordinary event that continues to adversely affect the health of populations around the world, poses a risk of international spread and interference with international traffic, and requires a coordinated international response. As such, the Committee concurred that the COVID-19 pandemic remains a public health emergency of international concern (PHEIC) and offered the following advice to the Director-General.

The Director-General determined that the COVID-19 pandemic continues to constitute a PHEIC. He accepted the advice of the Committee to WHO and issued the Committee's advice to States Parties as Temporary Recommendations under the IHR...

::::::

Weekly operational update on COVID-19 - 12 July 2021

Overview

In this edition of the COVID-19 Weekly Operational Update, highlights of country-level actions and WHO support to countries include:

- Scaling up COVID-19 vaccination in Africa
- Supporting Malaysia's COVID-19 response and emergency preparedness
- Enhancing COVID-19 testing – an investment in health
- Biosafety and biosecurity training in Uzbekistan
- Renovation of biosafety laboratories: enabling advancements in Thailand
- Donating portable pulse oximeters to Belize
- 2020 Progress Report of the Incident Management Support Team for COVID-19 in WHO's Eastern Mediterranean Region
- Using OpenWHO to disseminate pandemic biosafety learning materials in Angola
- Preparing cities for health emergencies from all-hazards risks and WHO Partners Platform teaming up with ECHO to support the scale up and roll-out of COVID-19 vaccine doses
- Progress on a subset of indicators from the SPRP 2021 Monitoring and Evaluation Framework
- Updates on WHO's financing to support countries in SPRP 2021 implementation and provision of critical supplies.

Weekly epidemiological update on COVID-19 - 13 July 2021

Overview

Globally, in the past week the number of new cases and deaths both increased when compared to the previous week. Nearly 3 million new cases of COVID-19 were reported globally and with just under 56 000 new deaths in the past week; cumulative deaths have now surpassed 4 million. All Regions apart from the Region of the Americas reported increases in new cases in the past week and the largest increase in new deaths was observed in the African Region.

In this edition, two special focuses are provided:

- A synopsis of the latest WHO COVID-19 Rapid Risk Assessment, which aims to review the current status of global public health risks associated with the pandemic through an in-depth hazard, exposure and context assessment.
- A short update on the geographical distribution of SARS-CoV-2 Variants of Concern (VOCs) Alpha, Beta, Gamma and Delta.



Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 26 June 2021

For 22 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

[Update posted 15 July 2021; click on the link above for full scale view]

Vaccines		Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process								Guidance Document 15 July 2021	
Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***			
1.	BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized	31/2020			
							Finalized: – Baxter Oncology GmbH Germany (DP) – Novartis Switzerland – Mibe (Dermapharm) Germany (DP) – Pharmacia & Upjohn, Kalamazoo (DP) – PGS McPherson (DP) Diluent suppliers: – Pfizer Perth, Australia – Fresenius Kabi, USA	30/06/2021 08/07/2021 16/07/2021 16/07/2021 16/07/2021	18 June 2021 18 June 2021		
2.	AZD1222	EMA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Core data finalized	16 April 2021			
							Data for Covax sites expected in April 2021 onwards – Westchester US (DP)	Finalized: SK-Catalent Wuxi (DS) Chemo Spain	16 April 2021 30 April 2021 04 June 2021		
3.	AZD1222	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021			
4.	Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021			
5.	Ad26.COV2.S	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	✓	Core data finalized (US +NL sites)	12 March 2021			
							Additional sites: - Aspen RSA (DP) - Catalent Aagni Italy (DP) - Merck, Durham, UK (DS) - Merck, West Point/PA (DP)	- Finalized - Finalized - Future submission - Future submission	- 25 June 2021 - 02 July 2021 - As submitted - As submitted		
6.	mRNA-1273	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	Finalized	30 April 2021			
							Additional sites, awaited: - ModernaTx, Novwood (DS) - Catalent Indiana, LLC (DP) - Lanza Biologics, Inc. Portsmouth, USA (DS) - Baxter, Bloomington, USA (DP)	• additional inf awaited • additional inf awaited • additional inf awaited • additional inf awaited	As submitted As submitted As submitted As submitted		

Vaccines								Guidance Document 15 July 2021	
	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
7.	 Sinopharm / BIBP ¹	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized	07 May 2021
8.	 SINOVAC	COVID-19 Vaccine (Vero Cell), Inactivated/ CoronaVac ²	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized	01 June 2021
9.	 THE GAMALEYA NATIONAL CENTER	Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings have been and continue to be held.	"Rolling" submission of clinical and CMC data has started.	Additional data (Non-CLIN, CLIN, CMC) Required. Following up on inspection observations.	Anticipated date will be set once all data is submitted and follow-up of inspection observations completed.
10.	 AstraZeneca ³	AZD1222	Japan MHLW/PMDA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	Submission from AZ received on 15 June. MHLW submitted review and GMP reports on 16 June 2021 and June 22.	Several meetings held separately with AZ and MHLW/PMDA	✓	Finalized	09 July 2021
11.	 AstraZeneca ³	AZD1222	Australia TGA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	Submission from AZ received on 11 June	Several meetings held separately with AZ and TGA	✓	Finalized	09 July 2021
12.	Bharat Biotech, India	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)/ COVAXIN	DCGI	Whole-Virion Inactivated Vero Cell	✓	✓	Rolling data started 06 July 2021	Ongoing	To be confirmed
13.	 CanSinoBIO	Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓	Rolling data starting August 2021		
14.	 NOVAVAX	NVX-CoV2373/Covaxov	EMA	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant.	✓	✓			
15.	 Sinopharm / WIBP ³	Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	Inactivated, produced in Vero cells	✓	✓			
16.	 CUREVAC ⁴	Zorecimeran (INN) concentrate and solvent for dispersion for injection; Company code: CVnCoV/CV07050101	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	Planned for Q4 of 2021			
17.	Sanofi Pasteur	CoV2 pre5 dTM-AS03 vaccine	EMA	Recombinant, adjuvanted	✓	✓			
18.	Vector State Research Centre of Virology and Biotechnology	EpiVacCorona	Russian NRA	Peptide antigen	Letter received not EOI. Reply sent on 15/01/2021				
19.	Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	Response to 2 nd EOI sent 29 Jan 2021. Additional information requested.				

Vaccines								Guidance Document 15 July 2021	
	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
20.	IMBCMS5, China	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development				
21.	Clover Biopharmaceuticals	SCB-2019	EMA	Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein	In discussion on submission strategy and timelines				
22.	BioCubaFarma - Cuba	Soberana 01, Soberana 02, Soberana Plus Abdala	CECMED	SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or aluminum	Awaiting information on strategy and timelines for submission.				

1. Beijing Institute of Biological Products Co-Ltd

2. Wuhan Institute of Biological Products Co Ltd

* Dossier Submission dates: more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission.

**Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant; 4. Risk-benefit decision; 5. Final decision made

*** Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.



COVID Vaccine Developer/Manufacturer Announcements [relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

AstraZeneca

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias

[Website not responding at inquiry]

CanSinoBIO

News - No new digest announcements identified

Clover Biopharmaceuticals - China
[News](#) - No new digest announcements identified

Curevac [Bayer Ag – Germany]
[News](#) - No new digest announcements identified

Gamaleya National Center
[Latest News and Events](#) - No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
[Home](#) - No new digest announcements

Janssen/JNJ
[Press Releases](#)

Jul 149, 2021 United States

[Johnson & Johnson Single-Shot COVID-19 Vaccine Demonstrated a Durable Immune Response and Elicited Dual Mechanisms of Protection Against Delta and Other SARS-CoV-2 Variants of Concern in Data Published in New England Journal of Medicine](#)

Jul 12, 2021 United States

[Johnson & Johnson Statement on COVID-19 Vaccine \(7/12\)](#) [Guillain-Barré syndrome]

Moderna
[Press Releases](#)

July 12, 2021

[Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine](#)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 12, 2021-- **[Moderna, Inc.](#)** (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a supply agreement with the government of Argentina for 20 million doses of Moderna's COVID-19 vaccine or its updated variant booster vaccine candidate, if authorized, to begin delivery in the first quarter of 2022...

Novavax
[Press Releases](#) - No new digest announcements identified

Pfizer
[Recent Press Releases](#) - No new digest announcements identified

Sanofi Pasteur
[Press Releases](#) - No new digest announcements identified :

July 10 2021 *Press releases*

[MenQuadfi® demonstrates superior immune response against serogroup C meningococcal disease in toddlers](#)

Serum Institute of India
[NEWS & ANNOUNCEMENTS](#) - No corporate announcements identified

[Last media release still posted is dated February 15, 2021; media release of April 21, 2021 apparently removed]

See production agreement for Sputnik vaccine below

Sinopharm/WIBPBIBP

[News](#) - No new digest announcements identified

Sinovac

[Press Releases](#)

SINOVAC Enters Into Agreement to Supply CoronaVac® to COVAX

BEIJING, China, July 12, 2021 -- SINOVAC Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that it had signed an advance purchase agreement (APA) with the Global Alliance for Vaccines and Immunization (Gavi Alliance), which is on behalf of COVAX Facility, to provide up to 380 million doses of inactivated COVID-19 vaccine, CoronaVac® for distribution under COVAX Facility.

According to the APA, SINOVAC will supply 50 million doses of CoronaVac® by the end of September of 2021. In addition, Gavi has the option to purchase an additional 150 million doses in the fourth quarter of 2021 and 180 million more doses in the first half of 2022. In total, up to 380 million doses of CoronaVac® will be available to both self-financing participants of the Facility as well as those supported by the Gavi COVAX AMC...

Mr. Weidong Yin, Chairman, President, and CEO of SINOVAC said, "Our mission at Sinovac is to supply vaccines in an effort to eliminate human disease. We appreciate the efforts from international organizations, including WHO and COVAX partners, to accelerate the efforts of disease prevention. Sinovac has delivered over one billion doses globally as of the end of June 2021 with the aim of contributing to the accessibility and affordability of Covid-19 vaccines during this pandemic. Further, safety and regular transportation and storage condition of inactivated vaccine supports easy access to the vaccine in every corner on the globe."..

Vector State Research Centre of Virology and Biotechnology

[Home](#) - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

::::::

GSK

[Press releases for media](#) - No new digest announcements identified

SK Biosciences

[Press releases](#) - No new digest announcements identified

::::::

::::::

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 17 Jul 2021

An overview of information collected from publicly announced bilateral and multilateral supply agreements [Agreements view since last week's edition]



Deal date	Recipient	Deal type	Vaccine name	Vaccine developer	Manufacturer
7/6/2021	European Commission	Multilateral	Janssen Pharmaceuticals	Janssen	
7/6/2021	Tunisia	Bilateral	Janssen Pharmaceuticals	Janssen	
7/9/2021	Viet Nam	Bilateral	Sinopharm (Beijing)		Beijing Institute of Biological Products (CNBG)
7/12/2021	COVAX	Multilateral	Sinopharm (Beijing)		Beijing Institute of Biological Products (CNBG)

::::::

::::::

World Bank Vaccine Operations Portal

<https://www.worldbank.org/en/who-we-are/news/coronavirus-covid19/world-bank-support-for-country-access-to-covid-19-vaccines>

Countries receiving World Bank support for vaccines

As of July 1, 2021

This list of countries, project documents, and procurement

::::::

::::::

Duke – Launch and Scale Speedometer

TRACKING COVID-19 VACCINE PURCHASES ACROSS THE GLOBE

[accessed 17 July 2021]

No new data encountered.

::::::

::::::

Our World in Data

Coronavirus (COVID-19) Vaccinations


- 26.1% of the world population has received at least one dose of a COVID-19 vaccine.
- 3.61 billion doses have been administered globally, and 30.46 million are now administered each day.

- Only 1% of people in low-income countries have received at least one dose.

Daily COVID-19 vaccine doses administered per 100 people, Jul 16, 2021

Shown is the rolling 7-day average per 100 people in the total population. For vaccines that require multiple doses, each individual dose is counted.


Our World
in Data



COVID-19 vaccine doses administered per 100 people, Jul 16, 2021

For vaccines that require multiple doses, each individual dose is counted. As the same person may receive more than one dose, the number of doses per 100 people can be higher than 100.

Our World
in Data



Source: Official data collated by Our World in Data – Last updated 17 July 2021, 09:40 (London time) OurWorldInData.org/coronavirus • CC BY


Dec 2, 2020 — Jul 16, 2021

Share of the population fully vaccinated against COVID-19, Jul 16, 2021

Our World
in Data

Share of the total population that have received all doses prescribed by the vaccination protocol. This data is only available for countries which report the breakdown of doses administered by first and second doses.

[+ Add country](#)



Source: Official data collated by Our World in Data – Last updated 17 July 2021, 09:40 (London time)
OurWorldInData.org/coronavirus • CC BY

► Dec 27, 2020

Jul 16, 2021

:::::::
:::::::

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[Vaccines and Related Biological Products Advisory Committee](#)

::: No meetings scheduled

::::::

[White House \[U.S.\]](#)

[Briefing Room](#) – Selected Major COVID Announcements

[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)

July 16, 2021 • [Press Briefings](#)

[Remarks by Vice President Harris at a Vaccine Mobilization Event](#)

July 12, 2021 • [Speeches and Remarks](#)

::::::

[Joint CDC and FDA Statement on Vaccine Boosters](#)

July 08, 2021

The United States is fortunate to have highly effective vaccines that are widely available for those aged 12 and up. People who are fully vaccinated are protected from severe disease and death, including from the variants currently circulating in the country such as Delta. People who are not vaccinated remain at risk. Virtually all COVID-19 hospitalizations and deaths are among those who are unvaccinated. We encourage Americans who have not yet been vaccinated to get vaccinated as soon as possible to protect themselves and their community.

Americans who have been fully vaccinated do not need a booster shot at this time. FDA, CDC, and NIH are engaged in a science-based, rigorous process to consider whether or when a booster might be necessary. This process takes into account laboratory data, clinical trial data, and cohort data – which can include data from specific pharmaceutical companies, but does not rely on those data exclusively.

We continue to review any new data as it becomes available and will keep the public informed. We are prepared for booster doses if and when the science demonstrates that they are needed.

:::::
:::::

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

[News & Press Releases](#)

[News: International regulators work towards alignment on development and authorisation of second-generation COVID-19 vaccines \(new\)](#)

Last updated: 16/07/2021

Regulatory convergence is critical for expediting and streamlining global development and authorisation of new or modified COVID-19 vaccines to address emerging coronavirus variants. The important role of regulatory alignment is described in the [summary of the second workshop on COVID-19 vaccine development and virus variants](#), organised under the umbrella of the [International Coalition of Medicines Regulatory Authorities \(ICMRA\)](#), which has been published today.

COVID-19 variants have been emerging since March 2020, steadily spreading already before the start of the vaccination campaigns in Europe and abroad. In light of continued mutations and new variants emerging globally, medicines regulators from around the globe have stressed the urgent public health priority to streamline regulatory processes and requirements for the development of new and adaptations of already-approved vaccines to protect against current or future strains.

Workshop participants discussed key regulatory considerations related to the development of second-generation COVID-19 vaccines and booster doses. In particular, they exchanged views on the use of immunobridging (i.e. an approach to infer the likelihood of a vaccine's protective effect) in the assessment of second-generation COVID-19 vaccines, the design and use of controlled [clinical trials](#) (placebo or other controls), and correlates of immunity (i.e. levels of a specific immune marker that indicates optimal protection has been achieved) for vaccines against COVID-19. They also highlighted challenges and issues, such as authorisation of second-generation vaccines and alternative approaches to demonstrate vaccine [efficacy](#), where alignment between regulators is needed to respond to the emerging COVID-19 virus variants. The virtual workshop took place on 24 June 2021

[News: EMA and ECDC update on COVID-19 \(new\)](#)

Last updated: 14/07/2021

::::::

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates

SARS-CoV-2 resurgence in EU and EEA related to relaxation of non-pharmaceutical interventions and increasing spread of Delta variant

News story

16 Jul 2021

There has been a 64.3% increase of weekly COVID-19 cases compared to last week, according to ECDC's epidemic intelligence and TESSy data reported by EU and EEA countries, as of 15 July 2021.

EMA and ECDC update on COVID-19

News story

14 Jul 2021

Complete vaccination courses vital for maximum protection.

::::::


Total doses administered in EU/EEA countries

EU	EU/EEA
----	--------

Cumulative uptake of at least one dose among adults (18+) in EU/EEA	Cumulative uptake of full vaccination among adults (18+) in EU/EEA
66.3%	49.1%

Number of adults (18+) with at least one dose in EU/EEA	Number of full vaccinations among adults (18+) in EU/EEA
245,738,437	181,876,439

Progress in the vaccine uptake among adults (18+) in EU/EEA countries as of 2021-07-17



<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

::::::

European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

Press release 16 July 2021

European Green Deal: Commission proposes new strategy to protect and restore EU forests

Today, the European Commission adopted the New EU Forest Strategy for 2030, a flagship initiative of the European Green Deal that builds on the EU Biodiversity Strategy for 2030.

Press release 15 July 2021

EU founding values: Commission starts legal action against Hungary and Poland for violations of fundamental rights of LGBTIQ people

Equality and the respect for dignity and human rights are core values of the EU, enshrined in Article 2 of the Treaty of the European Union. The Commission will use all the instruments at its disposal to defend these values.

Press release 15 July 2021

Coronavirus: Over 3 million vaccines doses shared via the EU Civil Protection Mechanism

Following new offers of assistance from EU Member States to countries in need, the Commission has so far supported the sharing of over 3 million COVID-19 vaccines with countries outside of the EU through the European Civil Protection Mechanism...

Currently the EU is supporting the delivery of the following offers via the [European Civil Protection Mechanism](#):

Albania: 250 000 doses from Denmark and 30 000 from Latvia;

Bhutan: 129 000 vaccine doses from Denmark and 10 000 doses from Croatia;

Bosnia and Herzegovina: 250 000 doses from Denmark;

Kosovo: 250 000 doses from Denmark;

North Macedonia: 250 000 doses from Denmark;

Taiwan: 10 000 doses from Slovakia;

Tunisia: 50 400 doses from Latvia;

Ukraine: 500 000 doses from Denmark and 100 800 doses from Romania;

The following offers have already been delivered via the [European Civil Protection Mechanism](#):

Albania: 100 000 doses shared by Greece;

Bhutan: 121 900 vaccine doses delivered from Denmark;

Bosnia and Herzegovina: 120 000 doses delivered from Greece;

Cabo Verde: 150 150 doses shared by the Netherlands;

Kosovo: 182 900 vaccines doses delivered from Norway;

Moldova: 405 600 vaccine doses shared by Romania;

North Macedonia: 100 000 doses delivered from Greece;

Serbia: 50 400 doses shared by Romania;

Suriname: 156 000 doses shared by the Netherlands;

Press release 15 July 2021

Commission refers HUNGARY to the Court of Justice of the European Union for unlawfully restricting access to the asylum procedure

Today the Commission has decided to refer Hungary to the Court of Justice of the European Union for unlawfully restricting access to the asylum procedure in breach of Article 6 of the Asylum Procedures Directive (Directive 2013/32/EU).

Press release 12 July 2021

Humanitarian aid: EU mobilises €22 million to support most vulnerable in Iran and Pakistan

Today the Commission has announced renewed support for those most in need in Iran and Pakistan with €22 million in humanitarian aid.

Press release 10 July 2021


Taxation: Historic global agreement to ensure fairer taxation of multinational enterprises

The European Commission welcomes the historic global agreement endorsed by G20 Finance Ministers and Central Bank Governors today, which will bring fairness and stability to the international corporate tax framework.

:::::::
:::::::

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment

:::::::



Full scale, interactive dashboard available at: <https://africacdc.org/covid-19-vaccination/>

:::::::
:::::::

Africa: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

Sputnik V vaccine against coronavirus authorized in Nigeria

Press release, 15.07.2021

Single-dose Sputnik Light vaccine registered in Kazakhstan

Press release, 15.07.2021

RDIF and Serum Institute of India, the world's largest vaccine manufacturer by volume, to start production of Sputnik vaccine at Company's facilities in September

Press release, 13.07.2021

- Technology transfer process has already started; cultivation process has begun following the approval by the Drug Controller General of India (DCGI).
- The parties intend to produce over 300 million doses of the vaccine in India per year with the first batch expected in September 2021.

Moscow, July 13, 2021 – The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), and Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, today announced cooperation to produce the Russian Sputnik vaccine against coronavirus.

SII is the world's largest company in terms of COVID vaccines production with over 500 million doses manufactured. Through several strategic associations, SII has been front running India's fight against the pandemic. In addition to developing its own vaccine, it is currently manufacturing Covishield (developed by AstraZeneca-Oxford), Covovax (by Novavax) and conducting trials of Codagenix in UK.

The first batch of Sputnik vaccine is expected to be produced at SII's facilities in September. The parties intend to produce over 300 million doses of the vaccine in India per year...

Sputnik V vaccine effective against new variants of coronavirus, the Gamaleya Center study published in Vaccines leading international journal, shows

Press release, 12.07.2021

Sputnik V vaccine elicits high IGG antibodies and neutralizing antibodies titers, a study in Argentina published in international Cell Reports Medicine journal shows

Press release, 12.07.2021

Sputnik V vaccine demonstrates strong safety profile during vaccination campaign in San Marino

Press release, 11.07.2021

:::::

:::::

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
17 JuLY 2021, 08:00 IST
(GMT+5:30)

(↑↓ Status change since
yesterday)

Active (1.36%)

424025 (6397↓)

Discharged (97.31%)

30227792 (43916↑)

Deaths (1.33%)

413091 (560↑)

COVID-19 Vaccination
as on : 17 July 2021,
08:00 IST (GMT+5:30)

Total Vaccination : 39,96,95,879 (42,12,557↑)

Government of India – *Press Information Bureau*

Latest Press Releases

No new digest content identified.

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

No new digest content identified.

::::::

::::::

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

China provides 500m COVID-19 vaccine doses to intl community

2021-07-12

BEIJING — China has provided more than 100 countries and international organizations with 500 million doses of COVID-19 vaccines and concentrates, accounting for one-sixth of the current global COVID-19 vaccine production, a Foreign Ministry official told Xinhua on July 9.

Guo Xuejun, deputy director-general of the department of international economic affairs at the Foreign Ministry, said during an interview with Xinhua that China has also actively supported other developing countries in producing vaccines to expand the global vaccine capacity.

China has always accommodated domestic and foreign needs for COVID-19 vaccines, said Guo, adding that China opposes vaccine nationalism.

With the help of the Chinese government, Chinese vaccine enterprises have carried out joint vaccine production in countries including the UAE, Indonesia, Malaysia, Egypt, Brazil, Turkey, Pakistan and Mexico, with production exceeding 200 million doses, Guo said.

Among the 140 countries that have signed Belt and Road cooperation documents with China, 84 countries have proposed introducing Chinese vaccines in the first half of this year, said Guo, adding that China has made a positive response to all these countries and provided vaccines...

::::::

::::::

::::::

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

Polio this week as of 14 July 2021

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

- :: Nigeria: one cVDPV2 case and two cVDPV2 positive environmental samples
- :: Senegal: two cVDPV2 cases and two cVDPV2 positive environmental samples
- :: Sierra Leone: one cVDPV2 positive environmental sample
- :: Somalia: one cVDPV2 positive environmental sample
- :: Tajikistan: one cVDPV2 case

:::::::
::::::

WHO/OCHA Emergencies

Editor's Note:

WHO has apparently reorganized and fundamentally shifted how it judges and tracks "emergencies". We found no announcement of descriptive information to share and present the webpage structure as encountered below. Obviously, the dates associated with some of these emergencies suggest that this is an archival platform as well as a current emergencies resource.

Health emergencies list - WHO

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

Crisis in Tigray, Ethiopia

:: [Ethiopia - Tigray Region Humanitarian Update](#) Situation Report Last updated: 9 Jul 2021

Ebola outbreak, Democratic Republic of the Congo, 2021

[Last apparent update: 3 May 2021]

Ebola outbreak outbreak, N'Zerekore, Guinea, 2021 [Last apparent update: 3 May 2021]

Coronavirus disease (COVID-19) pandemic [Last apparent update 16 July 2021; See COVID above]

Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020 [Last apparent update: 1 June 2021]

Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020 [Last apparent update: 3 May 2021]

Ebola outbreak, Democratic Republic of the Congo, 2018 [Last apparent update: 24 July 2018]

Yemen crisis [Last apparent update: 12 February 2021]

Syria crisis [Last apparent update: 18 June 2021]

Somalia crisis [Last apparent update: 24 March 2018]

Nigeria crisis [Last apparent update: 9 May 2018]

Ebola outbreak, Democratic Republic of the Congo, 2017 [Last apparent update: 3 May 2021]

Zika virus disease outbreak, 2015-2016 [Last apparent update: 24 Jan 2020]

Ebola outbreak: West Africa, 2014-2016 [Last apparent update: 3 May 2021]

Iraq crisis [Last apparent update: 9 Jan 2008]

South Sudan crisis [Last apparent update: 23 Sep 2020]

Avian influenza A (H7N9) virus outbreak [Last apparent update: 21 May 2021]

Middle East respiratory syndrome (MERS-CoV) outbreak [Last apparent update: 8 July 2019]

Influenza A (H1N1) virus, 2009-2010 pandemic [Last apparent update: 10 Aug 2010]

::::::

UN OCHA – Current Emergencies

Current Corporate Emergencies

Northern Ethiopia

[No new digest content identified]

::::::

::::::

WHO & Regional Offices [to 17 Jul 2021]

<https://www.who.int/>

16 July 2021

Departmental news

Germany reinforces its commitment to support WHO's work

16 July 2021

Departmental news

Investing in new TB vaccines: It's time to end the century-long wait!

16 July 2021

Departmental news

New findings from the ODYSSEY trial confirm superiority of dolutegravir-based ART in young children

16 July 2021

Departmental news

WHO publishes new Consolidated HIV guidelines for prevention, treatment, service delivery & monitoring

15 July 2021

News release

COVID-19 pandemic leads to major backsliding on childhood vaccinations, new WHO, UNICEF data shows

15 July 2021

Statement

Statement on the eighth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic

15 July 2021

Departmental news

WHO warns that HIV infection increases risk of severe and critical COVID-19

::::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: Home-based care boosts Nigeria's COVID-19 fight 15 July 2021

WHO Region of the Americas PAHO

No new digest content identified

WHO South-East Asia Region SEARO

No new digest content identified

WHO European Region EURO

:: WHO/Europe shows high rates of COVID-19 vaccination in prisons 16-07-2021

:: Access to health care is the best way to protect prisons from COVID-19 16-07-2021

:: Varied impact of COVID-19 on routine immunization in the European Region 16-07-2021

WHO Eastern Mediterranean Region EMRO

:: WHO/Europe shows high rates of COVID-19 vaccination in prisons 16-07-2021

:: Access to health care is the best way to protect prisons from COVID-19 16-07-2021

:: Varied impact of COVID-19 on routine immunization in the European Region 16-07-2021

WHO Western Pacific Region

No new digest content identified

::::::

New WHO Publications [Selected]

<https://www.who.int/publications/i>

WHO SAGE Roadmap For Prioritizing Uses Of COVID-19 Vaccines In The Context Of Limited Supply

An approach to inform planning and subsequent recommendations based upon epidemiologic setting and vaccine supply scenarios

16 July 2021

Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021

15 July 2021

COVID-19 Vaccines: safety surveillance manual. Module on safety surveillance of COVID-19

12 July 2021

Overview

The module provides an overview of factors to consider when monitoring the safety of COVID-19 vaccines administered to pregnant and breastfeeding women. It describes how national routine AEFI surveillance should be adapted to cater for this specific group of population using both passive and active surveillance methods. Specific considerations and limitations of each method are provided as well as tools for implementation.

PDF: <https://apps.who.int/iris/rest/bitstreams/1355678/retrieve>

:::::

CDC/ACIP [U.S.] [to 17 Jul 2021]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements

:::::

MMWR News Synopsis Friday, July 16, 2021

:: [COVID-19 Vaccination Coverage Among Insured Persons Aged \$\geq 16\$ Years, by Race/Ethnicity and Other Selected Characteristics — Eight Integrated Health Care Organizations, United States, December 14, 2020–May 15, 2021](#)

:: [COVID-19 Vaccine Administration, by Race and Ethnicity — North Carolina, December 14, 2020–April 6, 2021](#)

:: [Acceptability of Adolescent COVID-19 Vaccination Among Adolescents and Parents of Adolescents — United States, April 15–23, 2021 \(Early Release July 9, 2021\)](#)

:: [SARS-CoV-2 B.1.617.2 \(Delta\) Variant COVID-19 Outbreak Associated with a Gymnastics Facility — Oklahoma, April–May 2021 \(Early Release July 9, 2021\)](#)

:::::

Coronavirus Disease 2019 (COVID-19)- CDC

Approximately 50 announcements/reports/data summaries.

:::::

:::::

Africa CDC [to 17 Jul 2021]

<http://www.africacdc.org/>

News

Press Releases

Statement on the remarkable progress made by several African countries as part of the Partnerships for African Vaccine Manufacturing (PAVM)

13 July 2021

Press Releases

Wearing A Mask Still Matters: The World Rallies to Continue Masking to Stop the Spread of COVID-19

12 July 2021

:::::

:::::

China CDC <http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 17 Jul 2021]

<http://en.nhc.gov.cn/>

News

July 17: Daily briefing on novel coronavirus cases in China

On July 16, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 30 new cases of confirmed infections.

China provides 500m COVID-19 vaccine doses to intl community

2021-07-12

BEIJING — China has provided more than 100 countries and international organizations with 500 million doses of COVID-19 vaccines and concentrates, accounting for one-sixth of the current global COVID-19 vaccine production, a Foreign Ministry official told Xinhua on July 9.

Guo Xuejun, deputy director-general of the department of international economic affairs at the Foreign Ministry, said during an interview with Xinhua that China has also actively supported other developing countries in producing vaccines to expand the global vaccine capacity.

China has always accommodated domestic and foreign needs for COVID-19 vaccines, said Guo, adding that China opposes vaccine nationalism.

With the help of the Chinese government, Chinese vaccine enterprises have carried out joint vaccine production in countries including the UAE, Indonesia, Malaysia, Egypt, Brazil, Turkey, Pakistan and Mexico, with production exceeding 200 million doses, Guo said.

Among the 140 countries that have signed Belt and Road cooperation documents with China, 84 countries have proposed introducing Chinese vaccines in the first half of this year, said Guo, adding that China has made a positive response to all these countries and provided vaccines...

National Medical Products Administration – PRC [to 17 Jul 2021]

<http://english.nmpa.gov.cn/news.html>

News

Vaccination push extends to teenagers

2021-07-16

Some local governments in China are planning to administer COVID-19 vaccines to teenagers as the country pushes ahead with its mass immunization drive, with over 1.4 billion doses already administered.

The health commission in the Guangxi Zhuang autonomous region said on Tuesday that it will focus on vaccinating those aged 12 to 17 and the elderly in the second half of this year...

Over 1.4b doses of COVID-19 vaccines administered in China

2021-07-15

Over 1.4 billion doses of COVID-19 vaccines have been administered in China as of Tuesday, as the country continues to ramp up its inoculation drive, the National Health Commission said on July 14.

CCDC Weekly - Weekly Reports: Current Volume (3)

2021-07-16 / No. 29

[PDF of this issue](#)

[Preplanned Studies: Prevalence of Antimicrobial Resistant of Vibrio parahaemolyticus Isolated from Diarrheal Patients — Six PLADs, China, 2016–2020](#)

:::::

:::::

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 17 Jul 2021]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

News

No new digest content identified.

BARDA – U.S. Department of HHS [to 17 Jul 2021]

<https://www.phe.gov/about/barda/Pages/default.aspx>

News

No new digest content identified.

BMGF - Gates Foundation [to 17 Jul 2021]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 17 Jul 2021]

<https://www.gatesmri.org/>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
No new digest content identified.

CARB-X [to 17 Jul 2021]

<https://carb-x.org/>

News

No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 17 Jul 2021]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: [NEW] ***Informed Consent: A Monthly Review – July 2021*** is now posted [here](#)

CEPI – Coalition for Epidemic Preparedness Innovations [to 17 Jul 2021]

<http://cepi.net/>

Latest News

[CEPI launches COVAX Marketplace to match buyers and sellers of critical manufacturing supplies and speed up global access to COVID-19 vaccines through COVAX](#)

15 Jul 2021

[See COVAX above for detail]

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 17 Jul 2021]

<https://cioms.ch/>

News; Publications

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [to 17 Jul 2021]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 17 Jul 2021]

<https://dukeghic.org/>

No new digest content identified.

EDCTP [to 17 Jul 2021]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

16 July 2021

Biofabri and IAVI announce partnership to advance MTBVAC into efficacy trials

Biofabri and IAVI have announced their intention to partner on efficacy trials of the tuberculosis (TB) vaccine candidate MTBVAC. This highly promising vaccine candidate has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults...

Emory Vaccine Center [to 17 Jul 2021]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 17 Jul 2021]

<http://www.euvaccine.eu/>

Latest News

No new digest content identified

FDA [to 17 Jul 2021]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

July 16, 2021 - Coronavirus (COVID-19) Update: July 16, 2021

Today, as [Pfizer has announced](#)[External Link Disclaimer](#), the FDA has formally accepted the company's Biologics License Application (BLA) requesting licensure (approval) of the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 in individuals 16 years of age and older and has granted the application priority review. Currently, the vaccine is authorized for emergency use to prevent COVID-19 in individuals ages 12 and older. The Prescription Drug User Fee (PDUFA) Goal Date of January 2022 reflects the PDUFA deadline for Priority Review and does not mean approval will not happen before that time. Quite to the contrary, the review of this BLA has been ongoing, is among the highest priorities of the agency, and the agency intends to complete the review far in advance of the PDUFA Goal Date.

July 13, 2021 - Coronavirus (COVID-19) Update: July 13, 2021

Today, the FDA is announcing revisions to the vaccine recipient and vaccination provider fact sheets for the Johnson & Johnson (Janssen) COVID-19 Vaccine to include information pertaining to an observed increased risk of Guillain-Barré Syndrome (GBS) following vaccination.

Fondation Merieux [to 17 Jul 2021]

<http://www.fondation-merieux.org/>

News, Events

Announcement

IRD and the Mérieux Foundation renew their agreement and strengthen their cooperation on healthcare and research relating to infectious diseases

July 7, 2021, Global

Gavi [to 17 Jul 2021]

<https://www.gavi.org/>

News Releases

16 July 2021

US-donated vaccine deliveries to Africa set to begin, with first deliveries planned to Burkina Faso, Djibouti, and Ethiopia

[See COVAX above for detail]

12 July 2021

Gavi signs agreements with Sinopharm and Sinovac for immediate supply to COVAX

[See COVAX above for detail]

GHIT Fund [to 17 Jul 2021]

<https://www.ghitfund.org/newsroom/press>

GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that
July 15, 2021

GHIT Fund Announces New Investment: 97.4 Million Yen to Identify Novel Dual-Acting Bactericidal Drug Targets Against Mycobacterium Tuberculosis

Global Fund [to 17 Jul 2021]

<https://www.theglobalfund.org/en/news/>

News & Stories

News

Global Fund Applauds Switzerland's Leadership in The Global Fight Against COVID-19

14 July 2021

The Global Fund to Fight AIDS, Tuberculosis and Malaria praised the decision by the Swiss Federal Council to make available CHF300 million to the Access to COVID-19 Tools (ACT) Accelerator – a ground-breaking global collaboration of leading public health agencies to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines, while strengthening health systems. This new commitment follows an earlier announcement made in 2020 by the Swiss Federal Council of a CHF400 million contribution.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 17 Jul 2021]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 17 Jul 2021]

<http://www.hillemanlabs.org/>

Website reports "under maintenance" at inquiry

Human Vaccines Project [to 17 Jul 2021]

<http://www.humanvaccinesproject.org/>

News

News webpage not responding at inquiry

IAVI [to 17 Jul 2021]

<https://www.iavi.org/newsroom>

Latest News

PRESS RELEASES

Spanish pharmaceutical company Zendal and IAVI partner to advance the tuberculosis vaccine candidate MTBVAC into efficacy trials

- TB kills 1.4 million people a year, an infectious disease toll only recently surpassed by COVID-19.
- COVID-19 has reversed years of progress in TB response, costing additional lives and adding to the urgency of the global TB problem.
- MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.

PORRIÑO, SPAIN, and NEW YORK, U.S. — JULY 14, 2021 — Spanish biopharmaceutical company Biofabri and IAVI today announced their intention to partner on efficacy trials of the tuberculosis (TB) vaccine candidate MTBVAC.

was in-licensed and is being manufactured and developed by Biofabri, a subsidiary of the Zendal Group, in collaboration with University of Zaragoza, IAVI, and Europe-based Tuberculosis Vaccine Initiative (TBVI)...

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICRC [to 17 Jul 2021]

<https://www.icrc.org/en/whats-new>

Selected News Releases, Statements, Reports

Humanitarian space – or spaces – must be protected, without exception

Written statement by the International Committee of the Red Cross to the UN Security Council Briefing: Protection of Civilians in Armed Conflict: Preserving Humanitarian Space.

16-07-2021 | Statement

Ethiopia: Communities in Tigray hit hard by growing food and fuel prices

ICRC operational updated following the ongoing crisis that began with fighting nine months ago in the Tigray region.

15-07-2021 | News release

The World Bank, ICRC and UNICEF launch a report on joining forces in humanitarian and development collaboration to improve responses to protracted crises

Water and sanitation are priorities in both humanitarian and development work, but evidence shows that a lack of collaboration in conflict and violence-affected contexts between humanitarian and development support agencies is increasing costs, reduc

09-07-2021 | News release

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

COVAX begins vaccine rollout amid global supply challenges

09 Jul 2021

Camel riders traverse Northern Kenya to spread the word about COVID-19 vaccines. Planes bearing half a million vaccines touch down in Manila. Mongolian villagers gather in a health centre waiting room in Batumber. Around the world, millions of doses of COVID-19 vaccines have begun arriving through the COVAX Facility in the largest and most rapid g...

Monique Barbut, Hassatou N'Sele and Ingrid van Wees to join IFFIm Board of Directors

01 Jul 2021

New Board members bring diverse backgrounds in global development and finance

London, 1 July 2021 – IFFIm, the International Finance Facility for Immunisation, has appointed three new global development and finance executives to its Board of Directors. Monique Barbut, President of World Wildlife Fund (WWF) France, Hassatou Diop N'Sele, Treasurer...

IFRC [to 17 Jul 2021]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

IFRC warns only way to win race against variants is to boost vaccinations and protection measures

eneva, 16 July 2021 – The International Federation of Red Cross and Red Crescent Societies (IFRC) warns that the global vaccination rate must increase rapidly and protection measures upheld, if we are to win the race against more transmissible, and potentially more deadly, variants.

At least three quarters of people in most countries want to be vaccinated worldwide, in the face of emerging new variants, according to new survey data.¹ However, despite lofty rhetoric about global solidarity, there is a deadly gap in the global plan to equitably distribute COVID-19 vaccines. Only

around a quarter of the world's population have received at least one dose of the vaccine. This number drops dramatically in low-income countries, where only 1% of people have received one dose.² And some countries are yet to start mass vaccination campaigns.

Jagan Chapagain, Secretary General of the IFRC, said: "To world leaders we say, it is time to pull out all the stops to boost vaccine production. This includes a temporary waiver on intellectual property, as well as the sharing of knowledge and technology between countries. Vaccine equity is key to reducing the likelihood of variants and saving lives by limiting the spread of the virus. This is the only way we can truly end this pandemic.

"The IFRC is already playing its part to get vaccines into the arms of the most vulnerable, but in some countries, vaccination campaigns have hardly started. Our data shows that people want to be vaccinated, but production and vaccine dose sharing needs to happen much faster if we want vaccination to outpace the variants."...

Asia Pacific, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Thailand, Vietnam

South East Asia: COVID-19 vaccine divide widens as Delta surges

Kuala Lumpur/Jakarta/Geneva, 13 July 2021: A deadly wave of COVID-19 fuelled by the Delta variant is crashing into South East Asia as the International Federation of Red Cross and Red Crescent Societies warns of a widening global vaccine divide. Countr ...

13 July 2021

Institut Pasteur [to 17 Jul 2021]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

IOM / International Organization for Migration [to 17 Jul 2021]

<http://www.iom.int/press-room/press-releases>

News

IOM Provides Over 1,300 Migrants with Emergency Shelter and Assistance on the Canary Islands

2021-07-16 10:45

Madrid – As more migrants arrive in the Canary Islands, the International Organization for Migration (IOM) has provided shelter, protection services, medical, legal and other types of assistance to 1,361 migrants on Tenerife.

IOM Ethiopia Appeals for USD 40 Million to Assist Additional 1.6 Million People in Northern Ethiopia

2021-07-16 10:45

Addis Ababa – Nearly two million people affected by the crisis in northern Ethiopia desperately need life-saving assistance, including water, medicine and shelter, the International Organization for Migration (IOM) said today as it issued an urgent appeal for USD 40 million to...

Deaths on Maritime Migration Routes to Europe Soar in First Half of 2021: IOM Brief

2021-07-13 23:54

Berlin – At least 1,146 people died attempting to reach Europe by sea in the first six months of 2021 according to a new briefing released today by the International Organization for Migration (IOM).

Dominican Republic and IOM Help Clear Hurdles for 100,000 Venezuelan Migrants

2021-07-13 13:57

Santo Domingo – The first group of almost 100,000 Venezuelan migrants without legal status in the Dominican Republic have received visas allowing them to work, open bank accounts and join the social security system under the country's Migration Normalization Plan.

IVAC [to 17 Jul 2021]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

Webinar: Preventing the Next Pandemic: Vaccine Diplomacy, Surveillance and COVID Vaccines

When: Jul 30, 2021 at 11:00 AM Eastern Time

Description: Join Dr. Peter Hotez for a 60-minute webinar hosted by the International Vaccine Access Center to discuss topics ranging from vaccine diplomacy, the antivaccine movement, safety surveillance, and a new COVID vaccine.

IVI [to 17 Jul 2021]

<http://www.ivi.int/>

Selected IVI News, Announcements, Events

IVI welcomes Bangladesh as state party with ratification ceremony

July 15, 2021 – SEOUL, South Korea – The International Vaccine Institute (IVI) hosted a ceremony at headquarters today honoring the People's Republic of Bangladesh's ratification of the IVI Establishment Agreement. Over 20 years of vaccine research and capacity-building initiatives with partners in Bangladesh have led to significant achievements in global public health, including the domestic development and delivery of IVI's oral cholera vaccine, and IVI officially welcomes Bangladesh as its 19th state party.

JEE Alliance [to 17 Jul 2021]

<https://www.jeealliance.org/>

Selected News and Events

No new digest content identified.

Johns Hopkins Center for Health Security [to 17 Jul 2021]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

Johns Hopkins Center for Health Security Commends the Interacademy Partnership for Endorsing Tianjin Biosecurity Guidelines for Codes of Conduct for Scientists

July 14, 2021

Wednesday, July 14, 2021 – Advances in the biological sciences bring about wellbeing for humanity, but the same advances could be misused, particularly for the development and proliferation of biological weapons.

Since January 2021, the Johns Hopkins Center for Health Security has worked with Tianjin University, the Interacademy Partnership, with support from the US Department of State and the Chinese Ministry of Foreign Affairs to develop the [Tianjin Biosecurity Guidelines for Codes of Conduct for Scientists](#). The Codes of Conduct outline a set of guiding principles and standards of conduct for all involved in the biological sciences to guard against the misuse of biology and the development of biological weapons. The Tianjin Biosecurity Guidelines will help to prevent misuse of bioscience research without hindering beneficial outcomes, in accordance with the articles and norms of the Biological and Toxin Weapons Convention, and in advancement of progress towards achieving the UN Sustainable Development Goals.

:: [Read the Tianjin Biosecurity Guidelines for Codes of Conduct for Scientists.](#)

[**New Report: Carrying Equity in COVID-19 Vaccination Forward: Guidance Informed by Communities of Color**](#)

July 14, 2021

MSF/Médecins Sans Frontières [to 17 Jul 2021]

<http://www.msf.org/>

Latest [Selected Announcements]

South Sudan

[**South Sudan: 10 years of independence, violence, disease and dire needs**](#)

Project Update 16 Jul 2021

Somalia

[**Increasing vaccination against measles in Lower Juba could prevent thousands of deaths**](#)

Project Update 14 Jul 2021

National Academy of Medicine - USA [to 17 Jul 2021]

<https://nam.edu/programs/>

Selected News/Programs

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 17 Jul 2021]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 17 Jul 2021]

<http://www.nih.gov/news-events/news-releases>

News Releases

[**NIH-funded study finds gene therapy may restore missing enzyme in rare disease**](#)

July 16, 2021 — Results provide hope for children with aromatic L-amino acid decarboxylase deficiency.

PATH [to 17 Jul 2021]

<https://www.path.org/media-center/>

Press Releases

PATH and Quansys Biosciences launch Q-Plex™ Human Environmental Enteric Dysfunction Diagnostic (11-Plex) to accelerate EED interventions

Effective and affordable new research diagnostic tool can measure up to 11 key biomarkers of environmental enteric dysfunction with a single test

July 14, 2021

New partnership launched to accelerate elimination of relapsing *P. vivax* malaria that poses a risk to an estimated 2.5 billion people worldwide

The Partnership for Vivax Elimination (PAVE) will support endemic countries in achieving their Plasmodium vivax (*P. vivax*) malaria elimination goals. PAVE will advance the development of quality-assured, child-friendly treatments for relapse prevention, and generate and consolidate evidence to support malaria-endemic countries in developing and implementing new strategies to eliminate *P. vivax* malaria.

July 14, 2021

Sabin Vaccine Institute [to 17 Jul 2021]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

No new digest content identified.

UNAIDS [to 17 Jul 2021]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

12 July 2021

UNAIDS saddened by the death of Geoff Makhubo, Executive Mayor of Johannesburg

UNHCR Office of the United Nations High Commissioner for Refugees [to 17 Jul 2021]

<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

Attacks by armed group displace 20,000 civilians in eastern DRC

16 Jul 2021

News comment: UNHCR latest update on deteriorating situation of Eritrean refugees in Tigray

This news comment is attributable to Ann Encontre, UNHCR Representative in Ethiopia

15 Jul 2021

Statement by UN High Commissioner for Refugees Filippo Grandi on the situation of Eritrean refugees in Ethiopia's Tigray Region

13 Jul 2021

UNHCR warns of imminent humanitarian crisis in Afghanistan

13 Jul 2021

UNICEF [to 17 Jul 2021]

<https://www.unicef.org/media/press-releases>

Press Releases, News Notes, Statements [Selected]

Statement

07/15/2021

[Syria: Up to 1 million people at risk due to severe interruptions to Alouk Water Station](#)

Joint statement by United Nations Resident Coordinator and Humanitarian Coordinator for Syria, Imran Riza, Regional Humanitarian Coordinator for the Syria Crisis, Muhamnad Hadi and UNICEF Regional Director for the Middle East and North Africa, Ted Chaiban

Press release

07/15/2021

[COVID-19 pandemic leads to major backsliding on childhood vaccinations, new WHO, UNICEF data shows](#)

23 million children missed out on basic childhood vaccines through routine health services in 2020, the highest number since 2009 and 3.7 million more than in 2019

[See COVID above for detail]

Statement

07/14/2021

[Statement on the arrival of the first batch of COVID-19 vaccines in Haiti](#)

Statement by Jean Gough, UNICEF Regional Director for Latin America and the Caribbean

Press release

07/14/2021

[Nearly 40 per cent of young people on the move identify education and training as top priorities, according to new UNICEF poll](#)

Press release

07/13/2021

[1 in 3 countries are not taking action to help students catch up on their learning post-COVID-19 school closures](#)

A new UNESCO, UNICEF, World Bank and OECD report documents education responses to COVID-19 in 142 countries

Statement

07/13/2021

[Message from UNICEF Executive Director Henrietta Fore to staff](#)

News note

07/12/2021

[UNICEF signs supply agreement for Sinopharm COVID-19 vaccine](#)

[See COVID above for detail]

Remarks

07/12/2021

UNICEF Executive Director Henrietta Fore's remarks at the launch of the State of Food Security and Nutrition in the World report 2021

Press release

07/12/2021

UN report: Pandemic year marked by spike in world hunger

Africa posting biggest jump. World at critical juncture, must act now for 2030 turnaround

Unitaid [to 17 Jul 2021]

<https://unitaid.org/>

Featured News

15 July 2021

FIND and Unitaid invest to support technology transfer and boost local production of COVID-19 rapid tests in low- and middle-income countries

- Technology transfer agreements signed to enable expanded production of high-quality antigen rapid tests in Africa and Latin America
- Agreements signed with DCN Dx to transfer know-how to WAMA Diagnóstica (Brazil), and Bionote and Mologic to transfer know-how to DIATROPIX of the Institut Pasteur de Dakar (Senegal)
- Separate partnership between Viatris (South Africa) and Guangzhou Wondfo Biotech (China) supported to enable commercialization and distribution of high-quality Ag RDTs in low- and middle-income countries
- Agreements follow open call launched last year by FIND and Unitaid on behalf of the Access to COVID-19 Tools (ACT) Accelerator, to drive equitable access to rapid tests for COVID-19

14 July 2021

New Partnership launched to accelerate elimination of relapsing P. vivax malaria that poses a risk to an estimated 2.5 billion people worldwide

- The Partnership for Vivax Elimination (PAVE) will support endemic countries in achieving their Plasmodium vivax (P. vivax) malaria elimination goals.
- PAVE will advance the development of quality-assured, child-friendly treatments for relapse prevention, and generate and consolidate evidence to support malaria-endemic countries in developing and implementing new strategies to eliminate P. vivax malaria.

Vaccine Equity Initiative [to 17 Jul 2021]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin) [to 17 Jul 2021]

<https://www.vaccineacceptance.org/>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 17 Jul 2021]

<http://www.vaccineconfidence.org/>

News, Research and Reports

Coronavirus global impact

Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

Vaccine Education Center – Children's Hospital of Philadelphia [to 17 Jul 2021]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 17 Jul 2021]

<https://wellcome.ac.uk/news>

News and reports

No new digest content identified.

The Wistar Institute [to 17 Jul 2021]

<https://www.wistar.org/news/press-releases>

Press Releases

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 17 Jul 2021]

<https://www.wfpha.org/>

Latest News

No new digest content identified.

World Bank [to 17 Jul 2021]

<http://www.worldbank.org/en/news/all>

Selected News, Announcements

African Heads of State Call for an Ambitious Replenishment of the IDA20 to Support Their Recovery Agenda

ABIDJAN, July 15, 2021 – Thirteen African Heads of State and governments concluded their one-day meeting in Abidjan today with a strong resolution to accelerate economic...

Date: July 15, 2021 Type: Press Release

Statement July 15, 2021

Abidjan's Declaration

Following the Meeting of Heads of State and Government of Angola, Benin, Burkina Faso, Cameroon, Côte d'Ivoire, Democratic Republic of Congo, Ethiopia, Ghana, Guinea, Guinea Bissau, Kenya, Liberia, Madagascar, Mauritania, Mozambique, Niger, Nigeria, Uganda, Rwanda, Senegal, Sudan, Tanzania and Togo to Support A Twentieth (20th) Ambitious Replenishment of the Resources of the International Development Association (IDA20)

Food Security and COVID-19

July 16, 2021 -- An increasing number of countries are facing growing levels of acute food insecurity, reversing years of development gains. Even before COVID-19 reduced incomes and disrupted supply chains...

Date: July 14, 2021 Type: Brief

Africa's Scientific Solutions and Innovation in the Fight Against COVID-19

Challenge Increased productivity, economic diversification, and structural reforms across Africa will require the strategic production and retention of many highly skilled and employable graduates, particularly...

Date: July 14, 2021 Type: Result Brief

1 in 3 countries are not taking action to help students catch up on their learning post-COVID-19 school closures

A new UNESCO, UNICEF, World Bank and OECD Report documents education responses to COVID-19 in 142 countries

Date: July 13, 2021 Type: Press Release

Remarks by World Bank Group President David Malpass at the G20 Session on International Financial Architecture – Lead Intervention

VENICE, July 9, 2021 – Good afternoon. The recovery from the COVID-19 pandemic will require huge resources and coordination among development partners. Early in the pandemic, the World Bank...

Date: July 09, 2021 Type: Speeches and Transcripts

World Customs Organization – WCO [to 17 Jul 2021]

<http://www.wcoomd.org/>

Latest News – Selected Items

14 July 2021

Joint Indicative List of Critical COVID-19 Vaccine Inputs issued by the joint effort of WCO/WTO and other organizations

World Organisation for Animal Health (OIE) [to 17 Jul 2021]

<https://www.oie.int/en/for-the-media/press-releases/2021/>

Press Releases, Statements

Bridging partnerships towards the global control of African swine fever

News

12 July 2021

In the context of the global initiative for the control of African swine fever (ASF) launched in 2020, the Food and Agriculture Organization of the United Nations (FAO) and the World Organisation for Animal Health (OIE) have committed to create a forum of discussion between the public and the private sectors to discuss the latest findings and ways forward to control this deadly animal disease.

WTO - World Trade Organisation [to 17 Jul 2021]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events

[WTO issues joint indicative list of critical inputs for COVID-19 vaccines](#)

13 July 2021

The WTO Secretariat has published an indicative list compiling information on the critical inputs for the manufacturing, distributing and administering of COVID-19 vaccines. The list was jointly produced with the Asian Development Bank, the Organisation for Economic Cooperation and Development, the World Customs Organization, some COVID-19 vaccine manufacturers, researchers Chad Bown and Chris Rogers, the Coalition for Epidemic Preparedness Innovations and DHL.

[WTO holds two-day workshop on SPS risk analysis](#)

13 July 2021

The WTO held on 12-13 July a virtual Workshop on Risk Assessment, Risk Management and Risk Communication in relation to food safety, animal and plant health. With over 1,000 registered participants, the workshop brought together a variety of speakers from the public and private sector, academia, international standard-setting bodies and other international organizations for an in-depth discussion on all aspects of sanitary and phytosanitary (SPS) risk analysis.

::::::

ARM [Alliance for Regenerative Medicine] [to 17 Jul 2021]

[Press Releases - Alliance for Regenerative Medicine \(alliancerm.org\)](#)

Selected Press Releases

No new digest content identified.

BIO [to 17 Jul 2021]

[https://www.bio.org/press-releases](#)

Press Releases, Letters, Testimony, Comments [Selected]

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 17 Jul 2021]

[http://www.dcvmn.org/](#)

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 17 Jul 2021]

[https://internationalbiotech.org/news/](#)

News

No new digest content identified.

IFPMA [to 17 Jul 2021]

[http://www.ifpma.org/resources/news-releases/](#)

Selected Press Releases, Statements, Publications

COVAX launches Marketplace to match buyers and sellers of critical manufacturing suppliers and speed up

15 July 2021 – IFPMA welcomes the launch of an innovative 'marketplace'. The new Marketplace aims to accelerate the global production of COVID-19 vaccine doses for COVAX by matching suppliers of critical inputs with vaccine manufacturers who urgently need them to produce vaccines for fair and equitable distribution through COVAX. This initiative spearheaded by Coalition for Epidemic Preparedness Innovations (CEPI) is a key deliverable of the COVAX Manufacturing Task Force, which is co-led by COVAX and industry partners[1]...

International Alliance of Patients' Organizations – IAPO [to 17 Jul 2021]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest content identified.

PhRMA [to 17 Jul 202

<http://www.phrma.org/>

Latest News [Selected]

Promoting global vaccine equity while protecting innovation

July 15, 2021

The transformative promise of COVID-19 vaccines only extends as far as patients' ability to access them. Equitable distribution worldwide is critical. Despite significant cross-sector and multi-stakeholder efforts like COVAX, we are still seeing vaccine access and distribution challenges across many regions of the world due to complex barriers.

Blog Post

* * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 12, 2020 Issue 3

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 23, Number 6: E435-504 June 2021

<https://journalofethics.ama-assn.org/issue/transgenerational-trauma>

Transgenerational Trauma

One thing that makes trauma transgenerational is narrative. Narrative, for example, is what makes a Confederate flag from 1865 flint for insurrection in 2021. Consequences of global and domestic insults, such as slavery and forced migration, have long ramified intergenerationally in communities, families, and individuals' bodies. Legacies of trauma travel in stories across places and over time, and their effects include health status inequity and cumulative stress embodiment. Transmission of historically entrenched patterns of oppression also influence persons' lived experiences of marginalization, convey health risk, and can play out during clinical encounters.

American Journal of Infection Control

July 2021 Volume 49 Issue 7 p857-972

<http://www.ajicjournal.org/current>

Major Articles

Social dynamics of a population-level dashboard for antimicrobial stewardship: A qualitative analysis

Peter Taber, Charlene Weir, Jorie M. Butler, ... Matthew H. Samore, Matthew Bidwell Goetz, Peter A. Glassman

Published online: January 27, 2021

p862-867

Face masks to prevent transmission of COVID-19: A systematic review and meta-analysis

Yanni Li, Mingming Liang, Liang Gao,...Ce Cheng, Qin Zhou, Chenyu Sun

Published online: December 18, 2020

p900-906

American Journal of Preventive Medicine

July 2021 Volume 61 Issue 1 p1-148

<http://www.ajponline.org/current>

Research Articles

Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. Seniors

Kenneth J. Smith, Angela R. Wateska, Mary Patricia Nowalk,...Lee H. Harrison, William Schaffner, Richard K. Zimmerman

Published online: April 29, 2021

p28-36

Easing Human Papillomavirus Vaccine Hesitancy: A Communication Experiment With U.S. Parents

Parth D. Shah, William A. Calo, Melissa B. Gilkey,...Susan Alton Dailey, Karen G. Todd, Noel T. Brewer

Published online: May 08, 2021

p88-95

Published online: May 18, 2021

p105-114

Timeliness of Early Childhood Vaccinations and Undervaccination Patterns in Montana

Sophia R. Newcomer, Rain E. Freeman, Bekki K. Wehner, Stacey L. Anderson, Matthew F. Daley

Published online: May 08, 2021

e21-e29

Research Briefs

COVID-19 Case and Mortality Rates in the Federal Bureau of Prisons

Robin L. Toblin, Liesl M. Hagan

Published online: February 24, 2021

p120-123

Primary Immunization Series Coverage of Children With Sickle Cell Disease

Hannah K. Peng, Kevin J. Dombkowski, Gary L. Freed, Susan E. Creary, Dominic Smith, Sarah L.

Reeves

Published online: March 11, 2021

p124-127

American Journal of Public Health

June 2021 111(6)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 104 (2021): Issue 4 (Apr 2021)

<https://www.ajtmh.org/view/journals/tpmd/104/4/tpmd.104.issue-4.xml>

[Reviewed earlier]

Annals of Internal Medicine

June 2021 Volume 174, Issue 6

<http://annals.org/aim/issue>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 296 July 2021

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/296/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 17 Jul 2021)

[No new digest content identified]

BMJ Global Health

June 2021 - Volume 6 - 6

<https://gh.bmj.com/content/6/6>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 17 Jul 2021)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 17 Jul 2021)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 17 Jul 2021)

The CORBEL matrix on informed consent in clinical studies: a multidisciplinary approach of Research Infrastructures Building Enduring Life-science Services

Informed consent forms for clinical research are several and variable at international, national and local levels. According to the literature, they are often unclear and poorly understood by participants. Wit...

Authors: Cinzia Colombo, Michaela Th. Mayrhofer, Christine Kubiak, Serena Battaglia, Mihaela Matei, Marialuisa Lavitrano, Sara Casati, Victoria Chico, Irene Schluender, Tamara Carapina and Paola Mosconi

Citation: BMC Medical Ethics 2021 22:95

Content type: Research article

Published on: 17 July 2021

Consent to research participation: understanding and motivation among German pupils

The EU's 2006 Paediatric Regulation aims to support authorisation of medicine for children, thus effectively increasing paediatric research. It is ethically imperative to simultaneously establish procedures th...

Authors: Jana Reetz, Gesine Richter, Christoph Borzikowsky, Christine Glinicke, Stephanie Darabaneanu and Alena Buyx

Citation: BMC Medical Ethics 2021 22:93

Content type: Research article

Published on: 16 July 2021

Consent to research participation: understanding and motivation among German pupils

The EU's 2006 Paediatric Regulation aims to support authorisation of medicine for children, thus effectively increasing paediatric research. It is ethically imperative to simultaneously establish procedures th...

Authors: Jana Reetz, Gesine Richter, Christoph Borzikowsky, Christine Glinicke, Stephanie Darabaneanu and Alena Buyx

Citation: BMC Medical Ethics 2021 22:93

Content type: Research article
Published on: 16 July 2021

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 17 Jul 2021)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 17 Jul 2021)

[Influenza vaccination during pregnancy and influencing factors in Korea: A multicenter questionnaire study of pregnant women and obstetrics and gynecology doctors](#)

Although the World Health Organization and health authorities in most countries recommend that pregnant women receive inactivated influenza virus vaccines, coverage remains low. This study aimed to investigate...

Authors: Byung Soo Kang, San Ha Lee, Woo Jeng Kim, Jeong Ha Wie, In Yang Park and Hyun Sun Ko

Citation: BMC Pregnancy and Childbirth 2021 21:511

Content type: Research article

Published on: 16 July 2021

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 17 Jul 2021)

[No new digest content identified]

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 17 Jul 2021)

[No new digest content identified]

BMJ Evidence-Based Medicine

June 2021 - Volume 26 - 3

<https://ebm.bmj.com/content/26/3>

[Reviewed earlier]

BMJ Open

July 2021 - Volume 11 - 7

<https://bmjopen.bmj.com/content/11/7>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 99, Number 7, July 2021, 477-540

<https://www.ncbi.nlm.nih.gov/pmc/issues/384766/>

[Reviewed earlier]

Cell

Jul 08, 2021 Volume 184 Issue 14 p3591-3842

<https://www.cell.com/cell/current>

[Reviewed earlier]

Child Care, Health and Development

Volume 47, Issue 4 Pages: 411-574 July 2021

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 110, Issue 1 Pages: 1-262 July 2021

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

Volume 43 Issue 4 p651-792

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 18 Issue 3, June 2021

<https://journals.sagepub.com/toc/ctja/18/3>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 17 Jul 2021]

[No new digest content identified]

Contemporary Clinical Trials

Volume 106 July 2021

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/106/suppl/C>

[No new digest content identified]

The CRISPR Journal

Volume 4, Issue 3 / June 2021

<https://www.liebertpub.com/toc/crispr/4/3>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 9, issue 2, June 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-2>

[Reviewed earlier]

Current Opinion in Infectious Diseases

June 2021 - Volume 34 - Issue 3

<https://journals.lww.com/co-infectiousdiseases/pages/currrenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

Developing World Bioethics

Volume 21, Issue 2 June 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

Special Issue: Conscientious objection to termination of pregnancy in the global south: legal and ethical challenges

Issue Edited by: Anita Kleinsmidt

Development in Practice

Volume 31, Issue 4, 2021

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 2 - April 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 45, Issue 3 Pages: 499-737 July 2021

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

EMBO Reports

Volume 22 Issue 6 4 June 2021

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 27, Number 7—July 2021

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 35 June 2021

<https://www.sciencedirect.com/journal/epidemics/vol/35/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 149 - 2021

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 43, Issue 4 Pages: 1-44 July–August 2021

<https://onlinelibrary.wiley.com/toc/25782363/current>

Participants communicating online • Community perspectives in Malawi

Enrolling Children in Clinical Trials for Genetic Neurodevelopmental Conditions: Ethics, Parental Decisions, and Children's Identities

Erin Turbitt, Ainsley J. Newson, Barbara B. Biesecker, Benjamin S. Wilfond

Pages: 27-36

First Published: 01 July 2021

Abstract

Knowledge of genetic mechanisms contributing to neurodevelopmental conditions is advancing. This is informing development of new drugs to treat or ameliorate these conditions, through targeting underlying genetic pathways. Drugs are tested in clinical trials, necessitating parents to engage with decisions about whether to enroll their child. In this article, we consider important ethical issues to anticipate as clinical research opportunities in genetic neurodevelopmental conditions arise. For example, genetic pathways targeted by the drugs may interact with valued character and personality traits. It is essential that recruitment and consent processes are optimized for families who will grapple with whether these novel drug treatments interact with their child's personality and authentic identity. We call for focused social science research and further normative analysis so that parents are better supported to make informed choices. Additionally, clinical research regulators should have a sound

understanding of the contextual experiences regarding how this population of parents engages with decisions.

The European Journal of Public Health

SUPPLEMENT - Volume 31, Issue Supplement_1, July 2021

https://academic.oup.com/eurpub/issue/31/Supplement_1

Supplement: E-Mental-Health: Exploring the Evidence Base and Stakeholders' Perspectives on Internet-Based Interventions for the Prevention of Mental Health Conditions

Mental illness represents an enormous personal, social and societal burden for European citizens¹ calling for the need to expand existing models of mental healthcare delivery. In Europe, the Internet is a key source of health information,² and technology-enhanced (psychological) interventions such as Internet- and mobile-delivered applications ('eHealth³ and 'm-Health⁴) have become increasingly popular and studied. There is already strong evidence of the efficacy of online interventions for the prevention and treatment of several psychological disorders^{5,6} and meta-analyses show effect sizes similar to face-to-face interventions.⁷

Expert Review of Vaccines

Vol 20 (4) 2021

<https://www.tandfonline.com/toc/ierv20/current>

Review

Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies

Lianlian Bian, Fan Gao, Jialu Zhang, Qian He, Qunying Mao, Miao Xu & Zhenglun Liang

Pages: 365-373

Published online: 14 Apr 2021

Forum for Development Studies

Volume 48, 2021 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 17 Jul 2021]

Research Article metrics AWAITING PEER REVIEW

Using maternal and neonatal data collection systems for coronavirus disease 2019 (COVID-19) vaccines active safety surveillance in low- and middle-income countries: an international modified Delphi study [version 1; peer review: awaiting peer review]

Veronica Pingray, María Belizán, Sarah Matthews, Sabra Zaraa, Mabel Berrueta, Lisa M. Noguchi, Xu Xiong, Alejandra Gurtman, Judith Absalon, Jennifer C. Nelson, Lakshmi Panagiotakopoulos, Esperanca Sevane, Flor M. Munoz, Fernando Althabe, Kissa W. Mwamwitwa, Federico Rodriguez Cairoli, Steven A. Anderson, Elizabeth M. McClure, Christine Guillard, Annette Nakimuli, Andy Stergachis, Pierre Buekens
Peer Reviewers Invited

Funder - Bill and Melinda Gates Foundation

PUBLISHED 12 Jul 2021

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 17 Jul 2021]

An international policy on returning genomic research results

Authors: Anna C. F. Lewis, Bartha Maria Knoppers and Robert C. Green

Citation: Genome Medicine 2021 13:115

Content type: Comment

Published on: 15 July 2021

Abstract

The Global Alliance for Genomics and Health has approved a policy for the return of clinically actionable genomic research results, the first such policy approved by an international body. The policy acknowledges the potential medical benefits to millions of individuals who are participating in genomics research. It ties the pace of implementation to each country's clinical standards, including for the return of secondary findings, and urges funders to set aside resources to support responsible return.

Global Health Action

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 9, No. 2 June 30, 2021

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 17 Jul 2021]

Article

Israel: Family Court Authorizes Vaccination of Minors Without Father's Consent

In a decision rendered on July 1, 2021, the Haifa Family Court president, Judge Shelly Eisenberg, authorized a mother to vaccinate her two 15-year-old minors against the coronavirus despite their father's objection. According to the mother, the Ministry of Health had encouraged vaccination of minors ages 12–15 in view of the rise in infections in this ... Continue reading "Israel: Family Court Authorizes Vaccination of..."

Contributor: Levush, Ruth

Date: 2021-07-13

Global Public Health

Volume 16, Issue 7 (2021)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 17 Jul 2021]

[No new digest content identified]

Health Affairs

Vol. 40, No. 7 July 2021

<https://www.healthaffairs.org/toc/hlthaff/current>

July 2021 / Borders, Immigrants & Health

About one in seven residents of the US is an immigrant, and about fifteen million people live within 100 kilometers of the US-Mexico border. Disparities in health status exist between people born in the US and those who have immigrated. Immigration policy has been contentious throughout US history, and current policies in the US and Mexico have significant effects on the health and well-being of tens of millions of people. This thematic issue of *Health Affairs* focuses on immigrants and borders. The overview article by Arturo Vargas Bustamante and coauthors describes a range of health policy issues raised by the continuously shifting demography of US immigrants.

Health and Human Rights

Volume 22, Issue 1, June 2020

<https://www.hhrjournal.org/volume-22-issue-1-june-2020/>

Special Section: Mental Health and Human Rights

[Reviewed earlier]

Health Economics, Policy and Law

Volume 16 - Issue 3 - July 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 36, Issue 5, June 2021

<https://academic.oup.com/heapol/issue/36/5>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 17 Jul 2021]

[No new digest content identified]

Human Gene Therapy

Volume 32, Issue 11-12 / June 2021

<https://www.liebertpub.com/toc/hum/32/11-12>

[Reviewed earlier]

Humanitarian Exchange Magazine

Number 79, May 2021

<https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/>

Localisation and local humanitarian action

by HPN October 2020

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 17, Issue 5, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/content>

[Accessed 17 Jul 2021]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 17 Jul 2021]

[No new digest content identified]

International Health

Volume 13, Issue 4, July 2021

<https://academic.oup.com/inthealth/issue/13/4>

[Reviewed earlier]

International Human Rights Law Review

Volume 10 (2021): Issue 1 (Jun 2021)

<https://brill.com/view/journals/hrlr/10/1/hrlr.10.issue-1.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 8, No 5 (2021) May 2021

<https://www.ijcmph.com/index.php/ijcmph/issue/view/76>

[Reviewed earlier]

International Journal of Epidemiology

Volume 50, Issue 3, June 2021

<https://academic.oup.com/ije/issue>

[New issue; No digest content identified]

International Journal of Human Rights in Healthcare

Volume 14 Issue 1 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1>

Table of Contents

[Reviewed earlier]

International Journal of Infectious Diseases

Volume 107 p1-310

<https://www.ijidonline.com/current>

[Reviewed earlier]

JAMA

July 6, 2021, Vol 326, No. 1, Pages 11-96

<https://jamanetwork.com/journals/jama/currentissue>

Research Letter

[Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar](#)

Roberto Bertollini, MD, MPH; Hiam Chemaitelly, MSc; Hadi M. Yassine, PhD; et al.

free access has active quiz

JAMA. 2021;326(2):185-188. doi:10.1001/jama.2021.9970

This study explores the association of vaccination against COVID-19 or prior SARS-CoV-2 infection with PCR test positivity in airline passengers arriving in Qatar, February-April 2021.

JAMA Network**[COVID-19 Update July 17, 2021](#)**

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

July 2021, Vol 175, No. 7, Pages 663-756

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

Editorial

Rotavirus Vaccines—Going Strong After 15 Years

David I. Bernstein, MD, MA

online only

JAMA Pediatr. 2021;175(7):e210356. doi:10.1001/jamapediatrics.2021.0356

Original Investigation

Association of Rotavirus Vaccines With Reduction in Rotavirus Gastroenteritis in Children Younger Than 5 YearsA Systematic Review and Meta-analysis of Randomized Clinical Trials and Observational Studies

Zi-Wei Sun, MSc; Yu Fu, BS; Hai-Ling Lu, MD; et al.

online only

JAMA Pediatr. 2021;175(7):e210347. doi:10.1001/jamapediatrics.2021.0347

This meta-analysis synthesizes randomized clinical trials and observational studies to evaluate the comparative benefit, risk, and immunogenicity of different rotavirus vaccines.

July 12, 2021

Viewpoint online First

COVID-19 Vaccination of Minors Without Parental ConsentRespecting Emerging Autonomy and Advancing Public Health

Larissa Morgan, JD, MBE; Jason L. Schwartz, PhD; Dominic A. Sisti, PhD

free access

JAMA Pediatr. Published online July 12, 2021. doi:10.1001/jamapediatrics.2021.1855

This Viewpoint discusses allowing minors to consent and receive the COVID-19 vaccine without parental authorization.

JBI Evidence Synthesis

July 2021 - Volume 19 - Issue 7

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[New issue; No digest content identified]

Journal of Adolescent Health

July 2021 Volume 69 Issue 1 p1-180

<https://www.jahonline.org/current>

Original Articles

Urban-Rural Disparities in Vaccination Service Use Among Low-Income Adolescents

Yuping Tsai, Megan C. Lindley, Fangjun Zhou, Shannon Stokley

Published online: December 04, 2020

p114-120

Journal of Artificial Intelligence Research

Vol. 71 (2021)

https://www.jair.org/index.php/j_air

[Reviewed earlier]

Journal of Community Health

Volume 46, issue 3, June 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-3>

[Reviewed earlier]

Journal of Development Economics

Volume 151 June 2021

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/151/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 16 Issue 3, July 2021

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

June 2021 - Volume 75 - 6

<https://jech.bmjjournals.org/content/75/6>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 14, Issue 2 Pages: 83-169 May 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 16, Issue 3, 2020

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 32, Number 2, May 2021 Supplement

<https://muse.jhu.edu/issue/44396>

Table of Contents

[Overview of the Issue](#)

Kevin B. Johnson, [Tiffani J. Bright](#), [Cheryl R. Clark](#)

...The importance of techquity—defined as the strategic development and deployment of technology in health care and health to advance health equity—was even more apparent after the events of 2020. COVID-19 upended access to care and illuminated the impact of structural racism as a cause for a widening gap of access during the pandemic. Black Lives Matter became more than a trending hashtag on Twitter, or a movement resulting in peaceful protests and calls for policy reform: it put additional focus on the issue of race as a social and not a biological construct and called into question the rationale for common practices in health care that were triggered by race. A notable example was the emerging realization that kidney function assessment was tied to race and hardwired into many of our electronic health records. The real-world evidence around our lack of techquity was incontrovertible.

This Supplemental Issue of JHCPU provides articles that describe challenges to techquity, frameworks to improve the role of technology in care, and examples of how technology can transform health, public health, and health care...

Journal of Immigrant and Minority Health

Volume 23, issue 3, June 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-3>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 19, 2021_ Issue 2

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 224, Issue 2, 15 July 2021

<https://academic.oup.com/jid/issue/224/2>

VIRUSES

Influenza Vaccine Failure Associated With Age and Immunosuppression

Joanna Kimball, Yuwei Zhu, Dayna Wyatt, Christopher H Trabue, H Keipp Talbot

The Journal of Infectious Diseases, Volume 224, Issue 2, 15 July 2021, Pages 288–293,

<https://doi.org/10.1093/infdis/jiaa757>

Vaccine failure continues to be a challenge in our efforts to prevent influenza illnesses and hospitalizations. When evaluating influenza-vaccinated patients hospitalized with an influenza-like illness, older and immunosuppressed patients were found to be at increased risk for hospitalization with influenza.

Journal of Medical Ethics

July 2021 - Volume 47 - 7

<http://jme.bmjjournals.org/content/current>

COVID-19 current controversies

Allocation of COVID-19 vaccination: when public prioritisation preferences differ from official regulations (10 May, 2021) Free

Philipp Sprengholz, Lars Korn, Sarah Eitze, Cornelia Betsch

Development of a structured process for fair allocation of critical care resources in the setting of insufficient capacity: a discussion paper (20 November, 2020) Free

Tim Cook, Kim Gupta, Chris Dyer, Robin Fackrell, Sarah Wexler, Heather Boyes, Ben Colleypriest, Richard Graham, Helen Meehan, Sarah Merritt, Derek Robinson, Bernie Marden

Human rights and COVID-19 triage: a comment on the Bath protocol (16 April, 2021)

Vivek Bhatt, Sabine Michalowski, Aaron Wyllie, Margot Kuyle, Wayne Martin

Brief reports

Public involvement in the governance of population-level biomedical research: unresolved questions and future directions (6 October, 2020)

Sonja Erikainen, Phoebe Friesen, Leah Rand, Karin Jongsma, Michael Dunn, Annie Sorbie, Matthew McCoy, Jessica Bell, Michael Burgess, Haidan Chen, Vicky Chico, Sarah Cunningham-Burley, Julie Darbyshire, Rebecca Dawson, Andrew Evans, Nick Fahy, Teresa Finlay, Lucy Frith, Aaron Goldenberg, Lisa Hinton, Nils Hoppe, Nigel Hughes, Barbara Koenig, Sapfo Lignou, Michelle McGowan, Michael Parker, Barbara Prainsack, Mahsa Shabani, Ciara Staunton, Rachel Thompson, Kinga Varnai, Effy Vayena, Oli Williams, Max Williamson, Sarah Chan, Mark Sheehan

Journal of Patient-Centered Research and Reviews

Volume 8, Issue 2 (2021)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

[Reviewed earlier]

Journal of Pediatrics

Volume 234 p1-296

<http://www.jpeds.com/current>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 17 Jul 2021]

[No new digest content identified]

Journal of Public Health Management & Practice

July/August 2021 - Volume 27 - Issue 4

<https://journals.lww.com/jphmp/pages/currrenttoc.aspx>

Research Reports

Mitigating Ethical Risks in Public-Private Partnerships in Public Health

Yassany, Diana M.; Anason, Andrea P.; Barrett, Drue H.

Journal of Public Health Management and Practice. 27(4):E177-E182, July/August 2021.

Partnerships between the public and private sectors are necessary in public health and health care. Each partner provides skills, resources, and capabilities. When the public sector, including government, enters into a partnership with a nongovernmental or corporate entity, it is important to determine in

advance whether there are real or perceived ethical, financial, or programmatic risks to the organization that might need mitigation.

Journal of Public Health Policy

Volume 42, issue 2, June 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-2>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

July 2021 Volume 18 Issue 180

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 28, Issue 5, July 2021

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

May 2021; Volume 95, Issue 10

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Jul 17, 2021 Volume 398 Number 10296 p185-276, e7

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

COVID-19 in Africa: a lesson in solidarity

The Lancet

Many countries in Africa face a serious third wave of COVID-19 that is both larger and more burdensome on health systems than previous waves. This predictable turn of events has been driven by a morally reprehensible lack of vaccine equity (<1% of the population are fully vaccinated), leaving the continent vulnerable to new and more transmissible variants of the virus, behavioural and economic pandemic fatigue, and complacency. A lack of diagnostic capacity in some countries means the epidemiology of this current wave is uncertain, but South Africa, Namibia, and Zambia are reporting the highest numbers of new cases. The Delta variant has been detected in more than 14 countries across the region and pathogen genomic monitoring in South Africa shows that it is quickly

becoming the dominant variant there. Unless vaccines are rolled out quickly there will be subsequent waves of infection. But in the face of adversity, the African health community continues to work collaboratively, balancing short-term needs and long-term health security plans, and creating grounds for hope.

Collaboration and solidarity are prerequisites for success in a pandemic. Unfortunately, beyond scientific discovery, they have rarely been displayed globally. A [new report](#) from Chatham House explores the concept of solidarity in response to COVID-19. It highlights that international, regional, and within-country solidarity has been poor, but commends the alliance between the Africa Centres for Disease Control and Prevention, the African Union, and the WHO Regional Office for Africa in galvanising cooperation in the region. Together, this alliance has launched initiatives ranging from the Africa Medical Supplies Platform, which pools orders for medical supplies, to the Africa Vaccine Delivery Alliance, which aims to organise vaccine roll-out plans. [Rarely](#) for COVID-19 response leadership, women occupy key positions in these organisations. This progressive unity has been driven by local scientists and the health community and should be fully engaged with and amplified by all politicians of African Union member states.

One of the most promising results of this partnership is the acquisition of [400 million doses](#) of the Johnson & Johnson single-dose vaccine before the end of 2022. African Union member states can purchase the vaccine through a pooled procurement mechanism. When these vaccines will arrive is uncertain, and supply chains might slow delivery. But in theory, the deal should give countries a predictable supply of vaccine.

Implementation of vaccination programmes, though, is a challenge. 60% of countries with an extreme shortage of health-care workers are found in Africa. The continent has a population of 74 million people older than 60 years (of a total population of 1.3 billion), and many people who might be considered at high risk from COVID-19 because of comorbidities might be unaware, so prioritising groups for vaccination will need to be done locally. Although the vaccine doses themselves are funded, it is unclear how getting vaccines into people's arms will be financed. It is [estimated](#) that for every US\$1 spent on a COVID-19 vaccine dose, \$5 is needed for delivery. Even if the supply of Johnson & Johnson vaccine materialises in the coming months, vaccines are needed now. The need to vaccinate large proportions of the population while health systems strain under a third wave could have been avoided had international dissonance and vaccine nationalism not left African countries at the back of the vaccine queue. Nevertheless, the Johnson & Johnson vaccine should cover 30% of the population, COVAX should supply enough doses to cover 30% more, and, with additional bilateral agreements, more than 60% vaccine coverage can be achieved. These achievements in negotiating and organising this arrangement beg the question, why were African health leaders not more involved in the construction of COVAX?

There is a serious need and desire for Africa to take control of its own health security, so that countries can shape their future health. There is an ambitious drive for each country to have its own public health institution, supported by a centralised Africa Centres for Disease Control and Prevention, and a plan for the continent to manufacture its own vaccines, therapeutics, and diagnostics, with the public health workforce expanded to act as an epidemic response service.

The regional solidarity on display by many within the African health community has been impressive but can only go so far when international solidarity remains so derisory. A reckoning must be had over how the multilateral system approaches Africa, with a promise that no global health initiative,

foundation, or organisation is governed without involvement from African health leaders at every decision-making level.

Articles

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Mine Durusu Tanriover, et al. and the CoronaVac Study Group

The Lancet Child & Adolescent Health

Jul 2021 Volume 5 Number 7 p459-530

<https://www.thelancet.com/journals/lanchi/issue/current>

[New issue; No digest content identified]

Lancet Digital Health

Jul 2021 Volume 3 Number 7 e408-e461

<https://www.thelancet.com/journals/landig/issue/current>

[New issue; No digest content identified]

Lancet Global Health

Jul 2021 Volume 9 Number 7 e880-e1027

<https://www.thelancet.com/journals/langlo/issue/current>

Articles

Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study

Frédéric Debellut, et al

Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006–18: prospective observational time-series and case-control studies

Naor Bar-Zeev, et al for the VacSurv Consortium

Lancet Infectious Diseases

Jul 2021 Volume 21 Number 7 p889-1050, e182-e207

<https://www.thelancet.com/journals/laninf/issue/current>

Editorial

Should we vaccinate children against SARS-CoV-2?

The Lancet Infectious Diseases

Articles

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

Cristina Menni, et al.

Quantifying the global number of tuberculosis survivors: a modelling study

Peter J Dodd, Courtney M Yuen, Shamanthi M Jayasooriya, Marieke M van der Zalm, James A Seddon

Lancet Public Health

Jun 2021 Volume 6 Number 6 e346-e433

<https://www.thelancet.com/journals/lanpub/issue/current>

Editorial

HIV 40: inequalities fuel pandemics

The Lancet Public Health

Lancet Respiratory Medicine

Jul 2021 Volume 9 Number 7 p673-802, e56-e68

<https://www.thelancet.com/journals/lanres/issue/current>

[New issue; No digest content identified]

Maternal and Child Health Journal

Volume 25, issue 6, June 2021

<https://link.springer.com/journal/10995/volumes-and-issues/25-6>

[New issue; No digest content identified]

Medical Decision Making (MDM)

Volume 41 Issue 5, July 2021

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 99, Issue 2 Pages: 329-599 June 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Nature

Volume 595 Issue 7867, 15 July 2021

<https://www.nature.com/nature/volumes/595/issues/7866>

[New issue; No digest content identified]

Nature Biotechnology

Volume 39 Issue 7, July 2021

<https://www.nature.com/nbt/volumes/39/issues/7>

Patents | 13 July 2021

Ebola as a case study for the patent landscape of medical countermeasures for emerging infectious diseases

A survey of patenting activity can facilitate coordination of R&D activities to fight emerging infectious diseases.

Nasir Mohajel, Arash Arashkia

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 17 Jul 2021)

[No new digest content identified]

Nature Genetics

Volume 53 Issue 7, July 2021

<https://www.nature.com/ng/volumes/53/issues/7>

[New issue; No digest content identified]

Nature Human Behaviour

Volume 5 Issue 6, June 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/6>

[Reviewed earlier]

Nature Medicine

Volume 27 Issue 7, July 2021

<https://www.nature.com/nm/volumes/27/issues/7>

Comment | 24 June 2021

Transforming global health through equity-driven funding

Black people living in Africa must be involved in setting the priorities for global health research, policies and programs that affect their daily lives, in order to move away from a funding culture that fosters colonialism, racism and white supremacy.

Jacob O. Olusanya, Olufunmilayo I. Ubogu, Bolajoko O. Olusanya

Analysis | 18 May 2021

Equitable allocation of COVID-19 vaccines in the United States

An analysis of COVID-19 vaccine allocation frameworks in the United States across 64 Centers for Disease Control and Prevention jurisdictions reveals that, as of 31 March 2021, 37 jurisdictions had adopted disadvantage indices to reduce health disparities. The analysis also highlights the importance of vaccine prioritization based on health and place.

Harald Schmidt, Rebecca Weintraub, Angela A. Shen

Nature Reviews Genetics

Volume 22 Issue 7, July 2021

<https://www.nature.com/nrg/volumes/22/issues/7>

Review Article | 04 May 2021

Testing at scale during the COVID-19 pandemic

Population-scale testing is an essential component of responses to the COVID-19 pandemic and is likely to become increasingly important in public health. Here, Mercer and Salit describe the roles of testing during the COVID-19 pandemic, including in genomic surveillance, contact tracing and environmental testing.

Tim R. Mercer, Marc Salit

Nature Reviews Immunology

Volume 21 Issue 7, July 2021

<https://www.nature.com/nri/volumes/21/issues/7>

[New issue; No digest content identified]

Nature Reviews Drug Discovery

Volume 20 Issue 7, July 2021

<https://www.nature.com/nrd/volumes/20/issues/7>

An Audience With

[COVID-19 vaccine success enables a bolder vision for mRNA cancer vaccines, says BioNTech CEO](#)

Uğur Şahin, an oncologist and mRNA pioneer, discusses his firm's development plans for cancer vaccines, mRNA-encoded proteins and more.

Asher Mullard

New England Journal of Medicine

July 15, 2021 Vol. 385 No. 3

<http://www.nejm.org/toc/nejm/medical-journal>

Perspective

[Averting Future Vaccine Injustice](#)

S. Moon, A. Alonso Ruiz, and M. Vieira

Both rapid innovation and equitable access to vaccines are necessary to protect the world from viral pandemics. Today, however, we face gross inequities in global access to Covid-19 vaccines. As high-income countries, such as the United States and European countries, have secured a majority of the world's vaccine supply (more than twice the volumes needed to cover their populations¹), many low-income countries have barely begun the immunization process. It will take political courage to end such vaccine injustice now and political vision to negotiate the binding international rules needed to avert similar inequities in the future...

[Scaling Up Covid-19 Vaccination in Africa — Lessons from the HIV Pandemic](#)

J.B. Nachega, N.A. Sam-Agudu, J.W. Mellors, A. Zumla, and L.M. Mofenson

[Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents](#)

R.W. Frenck, Jr., and Others

Conclusions

The BNT162b2 vaccine in 12-to-15-year-old recipients had a favorable safety profile, produced a greater immune response than in young adults, and was highly effective against Covid-19. (Funded by BioNTech and Pfizer; C4591001 ClinicalTrials.gov number, [NCT04368728](https://clinicaltrials.gov/ct2/show/C4591001). [opens in new tab.](#))

Pediatrics

Vol. 148, Issue 1 1 Jul 2021

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

PharmacoEconomics

Volume 39, issue 6, June 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-6>

Themed issue : Economic Burden of Major Depressive Disorders

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 17 Jul 2021)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 17 Jul 2021)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 17 Jul 2021)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 17 Jul 2021)

Viewpoints

The Myanmar military coup: Propelling the 2030 milestones for neglected tropical diseases further out of reach

Bethany Moos, Russell Roberts, Mo Aye

| published 15 Jul 2021 PLOS Neglected Tropical Diseases

<https://doi.org/10.1371/journal.pntd.0009532>

PLoS One

<http://www.plosone.org/>

[Accessed 17 Jul 2021]

Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2

Madison Stoddard, Sharanya Sarkar, Lin Yuan, Ryan P. Nolan, Douglas E. White, Laura F. White, Natasha S. Hochberg, Arijit Chakravarty
Research Article | published 16 Jul 2021 PLOS ONE
<https://doi.org/10.1371/journal.pone.0254734>

The impact of vaccination to control COVID-19 burden in the United States: A simulation modeling approach

Oguzhan Alagoz, Ajay K. Sethi, Brian W. Patterson, Matthew Churpek, Ghalib Alhanaee, Elizabeth Scaria, Nasia Safdar
Research Article | published 14 Jul 2021 PLOS ONE
<https://doi.org/10.1371/journal.pone.0254456>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>
[Accessed 17 Jul 2021]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States of America

July 13, 2021; vol. 118 no. 28
<https://www.pnas.org/content/118/28>
[New issue; No digest content identified]

Prehospital & Disaster Medicine

Volume 36 - Issue 3 - June 2021
<https://www.cambridge.org/core/journalsprehospital-and-disaster-medicine/latest-issue>
[Reviewed earlier]

Preventive Medicine

Volume 147 June 2021
<https://www.sciencedirect.com/journal/preventive-medicine/vol/147/suppl/C>
[Reviewed earlier]

Proceedings of the Royal Society B

14 July 2021 Volume 288 Issue 1954
<https://royalsocietypublishing.org/toc/rspb/current>
[New issue; No digest content identified]

Public Health

Volume 195 Pages 1-160 (June 2021)
<https://www.sciencedirect.com/journal/public-health/vol/195/suppl/C>
[Reviewed earlier]

Public Health Ethics

Volume 14, Issue 1, April 2021

<http://phe.oxfordjournals.org/content/current>

[New issue; No digest content identified]

Public Health Reports

Volume 136 Issue 4, July/August 2021

<https://journals.sagepub.com/toc/phrg/136/4>

[Reviewed earlier]

Qualitative Health Research

Volume 31 Issue 8, July 2021

<http://qhr.sagepub.com/content/current>

[New issue; No digest content identified]

Research Ethics

Volume 17 Issue 2, April 2021

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 17 Jul 2021]

[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health
(RPSP/PAJPH)**

<https://www.paho.org/journal/en>

Selected Articles

[No new digest content identified]

Risk Analysis

Volume 41, Issue 6 Pages: 843-1045 June 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 17 Jul 2021]

[No new digest content identified]

Science

16 July 2021 Vol 373, Issue 6552

<http://www.sciencemag.org/current.dtl>

Policy Forum

Beware explanations from AI in health care

By Boris Babic, Sara Gerke, Theodoros Evgeniou, I. Glenn Cohen

Science 16 Jul 2021 : 284-286 Restricted Access

The benefits of explainable artificial intelligence are not what they appear

Summary

Artificial intelligence and machine learning (AI/ML) algorithms are increasingly developed in health care for diagnosis and treatment of a variety of medical conditions (1). However, despite the technical prowess of such systems, their adoption has been challenging, and whether and how much they will actually improve health care remains to be seen. A central reason for this is that the effectiveness of AI/ML-based medical devices depends largely on the behavioral characteristics of its users, who, for example, are often vulnerable to well-documented biases or algorithmic aversion (2). Many stakeholders increasingly identify the so-called black-box nature of predictive algorithms as the core source of users' skepticism, lack of trust, and slow uptake (3, 4). As a result, lawmakers have been moving in the direction of requiring the availability of explanations for black-box algorithmic decisions (5). Indeed, a near-consensus is emerging in favor of explainable AI/ML among academics, governments, and civil society groups. Many are drawn to this approach to harness the accuracy benefits of noninterpretable AI/ML such as deep learning or neural nets while also supporting transparency, trust, and adoption. We argue that this consensus, at least as applied to health care, both overstates the benefits and undercounts the drawbacks of requiring black-box algorithms to be explainable.

Science Translational Medicine

14 July 2021 Vol 13, Issue 602

<https://stm.sciencemag.org/>

[New issue; No digest content identified]

Social Science & Medicine

Volume 278 June 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/278/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 17 Jul 2021]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 41, issue 5-6, December 2020
<https://link.springer.com/journal/11017/volumes-and-issues/41-5>
[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 41 May–June 2021
<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/41/suppl/C>
[Reviewed earlier]

Tropical Medicine & International Health

Volume 26, Issue 7 Pages: i-iv, 715-837 July 2021
<https://onlinelibrary.wiley.com/toc/13653156/current>
[Reviewed earlier]

Vaccine

Volume 39, Issue 28 Pages 3645-3784 (23 June 2021)
<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/28>

Review article Abstract only

[A systematic review and meta-analysis of effectiveness of decision aids for vaccination decision-making](#)

Cassandra Vujovich-Dunn, Jessica Kaufman, Catherine King, S. Rachel Skinner, ... Julie Leask
Pages 3655-3665

Review article Abstract only

[A systematic review and meta-analysis of effectiveness of decision aids for vaccination decision-making](#)

Cassandra Vujovich-Dunn, Jessica Kaufman, Catherine King, S. Rachel Skinner, ... Julie Leask
Pages 3655-3665

Research article Abstract only

[Stopping a polio outbreak in the midst of war: Lessons from Syria](#)

Chukwuma Mbaeyi, Thomas Moran, Zubair Wadood, Fazal Ather, ... Magdi Sharaf
Pages 3717-3723

Research article Open access

[Human papillomavirus \(HPV\) vaccine uptake among a community-recruited sample of gay, bisexual, and other men who have sex with men in the three largest cities in Canada from 2017 to 2019](#)

R. Grewal, S.L. Deeks, T.A. Hart, J. Cox, ... A.N. Burchell
Pages 3756-3766

Research article Abstract only

[The impact of an educational forum intervention on East African mothers' HPV vaccine-related knowledge, attitudes, and intentions to vaccinate their adolescent children](#)

Huong Chu, Linda K. Ko, Anisa Ibrahim, Farah Bille Mohamed, ... Rachel L. Winer

Pages 3767-3776

Vaccines — Open Access Journal

<http://www.mdpi.com/journal/vaccines>

Open Access Article

Using Household Surveys to Assess Missed Opportunities for Simultaneous Vaccination: Longitudinal Examples from Colombia and Nigeria

by [Dale A. Rhoda](#), et al.

Vaccines 2021, 9(7), 795; <https://doi.org/10.3390/vaccines9070795> (registering DOI) - 16 Jul 2021

Abstract

One important strategy to increase vaccination coverage is to minimize missed opportunities for vaccination. Missed opportunities for simultaneous vaccination (MOSV) occur when a child receives one or more vaccines but not all those for which they are eligible at a given visit. Household [\[...\]](#)

Value in Health

July 2021 Volume 24 Issue 7 p917-1088

<https://www.valueinhealthjournal.com/current>

POLICY PERSPECTIVE

Measuring Attitudes About Genomic Medicine: Validation of the Genomic Orientation Scale (GO Scale)

Caroline Horow, Joel E. Pacyna, Minji K. Lee, Richard R. Sharp

Published online: April 02, 2021

p1030-1037

* * * *

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

The sheer volume of vaccine and pandemic-related coverage is extraordinary. We will strive to present the most substantive analysis and commentary we encounter.

The Atlantic

<http://www.theatlantic.com/magazine/>

Accessed 17 Jul 2021

Family

We Could Have Changed the World

The upheaval of the pandemic was an opportunity to imagine a better society. Instead, we're rushing back to "normal."

By Ekemini Uwan

BBC

<http://www.bbc.co.uk/>

Accessed 17 Jul 2021

[No new, unique, relevant content]

The Economist

<http://www.economist.com/>

Accessed 17 Jul 2021

Lexington

The Republican anti-vax delusion

America's vaccination programme is stalling. Populist conservatives are to blame
United States Jul 17th 2021 edition

The next catastrophe

A wave of covid-19 is engulfing Indonesia

The government's response is too little, too late

Jul 17th 2021 edition

Financial Times

<https://www.ft.com/>

Coronavirus pandemic

Top US health official warns of 'pandemic of the unvaccinated'

July 17, 2021

Forbes

<https://www.forbes.com/>

Accessed 17 Jul 2021

[No new, unique, relevant content]

Foreign Affairs

<http://www.foreignaffairs.com/>

Accessed 17 Jul 2021

[No new, unique, relevant content]

Foreign Policy

<http://foreignpolicy.com/>

Accessed 17 Jul 2021

[No new, unique, relevant content]

New Yorker

<http://www.newyorker.com/>

Accessed 17 Jul 2021

Medical Dispatch

Treating the Unvaccinated

In Utah, and across the U.S., doctors are facing a wave of preventable COVID deaths—and trying to convince the hesitant that “it doesn’t have to be this way.”

By [Dhruv Khullar](#)

July 16, 2021

New York Times

<http://www.nytimes.com/>

Accessed 17 Jul 2021

Politics

How Republican Vaccine Opposition Got to This Point

In recent months, Republican skepticism of Covid vaccines and their rollout has grown louder: One recent poll found that 47 percent said they weren’t likely to get vaccinated.

By Lisa Lerer July 17, 2021

Washington Post

<https://www.washingtonpost.com/>

Accessed 17 Jul 2021

France: Thousands protest against vaccination, COVID passes

· Jul 17, 2021

*

*

*

*

Think Tanks et al

Brookings

<http://www.brookings.edu/>

Accessed 17 Jul 2021

[No new digest content identified]

Center for Global Development [to 17 Jul 2021]

<http://www.cgdev.org/page/press-center>

Publication

What's Next? Predicting The Frequency and Scale of Future Pandemics

Event

7/20/21

Amid a pandemic, it is difficult to consider preparing for the next one, especially when there is no certainty about its timing. COVID-19 is broadly viewed as being a “once in a lifetime” or “once in a century” pandemic; unfortunately, that is not accurate. But what is the actual return time to a future pandemic threat, and how can we ensure that the world is prepared next time?

World Leaders: It Is Time for New Global Funding to Keep the World Safer from Pandemics

July 15, 2021

This past weekend, the [High-Level Independent Panel](#) on Financing the Global Commons for Pandemic Preparedness and Response delivered a stark warning in its [report](#) to the G20 Finance Ministers and Central Bank Governors meeting in Venice: With the near certainty of an even more deadly and costly

pandemic than COVID-19 occurring within the next decade, the clock is ticking to ramp up investments in international preparedness.

Amanda Glassman and Carolyn Reynolds

Chatham House [to 17 Jul 2021]

<https://www.chathamhouse.org/>

Accessed 17 Jul 2021

Research paper

Solidarity in response to the COVID-19 pandemic

Has the world worked together to tackle the coronavirus?

14 July 2021 ISBN: 978 1 78413 481 5

PDF: https://www.chathamhouse.org/sites/default/files/2021-07/2021-07-14-solidarity-response-covid-19-pandemic-rahman-shepherd-et-al_0.pdf

It has frequently been stated during the COVID-19 pandemic that 'no one is safe until we are all safe'. This is most commonly talked of between nations, but, importantly, it also applies within countries.

Besides the elderly, the pandemic has disproportionately affected the disadvantaged, the poor, the vulnerable, minorities, migrants and other neglected and marginalized groups, in all societies. It has been prolonged by the failure in many countries to adequately support and protect these groups. Where solidarity has been weak, inequities have widened, and effective responses to the pandemic have been frustrated.

This research paper assesses how the global community has responded to calls for greater solidarity in tackling the COVID-19 pandemic, and presents the insights of key stakeholders and experts in global health governance, health security, and pandemic preparedness and response. The authors examine the state of solidarity at global, regional and national levels, and present case studies on COVAX and on the EU's turbulent journey through solidarity.

CSIS

<https://www.csis.org/>

Accessed 17 Jul 2021

Critical Questions

Minding the Gap in Global Immunization Coverage

July 16, 2021 | By [Katherine E. Bliss](#)

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

July 16, 2021 *News Release*

KFF/UNAIDS Analysis Finds That While Donor Government Spending on HIV Increased in 2020, Future Funding is Uncertain with COVID-19 Challenges

A new report from KFF (Kaiser Family Foundation) and The Joint United Nations Programme on HIV/AIDS (UNAIDS) finds that donor government disbursements to combat HIV in low- and middle-income countries increased by US\$377 million in 2020, reaching US\$8.2 billion in 2020 compared to US\$7.8 billion in 2019. Donor government funding...

July 13, 2021 *News Release*

Vaccine Monitor: Some Who Were Hesitant to Get a Vaccine in January Say They Changed Their Mind Because of Family, Friends and Their Personal Doctors

A new KFF COVID-19 Vaccine Monitor report finds that people who were initially hesitant to get a vaccine in January but ultimately did so often say that family, friends and their personal doctors helped change their minds. The report features a second round of interviews with a nationally representative sample...

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *